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A B S T R A C T
The importance of making predictions in health is mainly linked to the decision-making
process. Make survival predictions accurately is a very difficult task for healthcare profes-
sionals and a major concern for patients. On the one hand, it can help physicians decide
between palliative care or other medical practice for a patient. On the other hand, the no-
tion of remaining lifetime could help patients in the realization of dreams. However, the
prediction of survivability is directly related to the experience of health professionals and
their ability to memorize.
Most decisions are made based on probability and statistics, but these are based on large
groups of people and may not be suitable to predict what will happen in particular cases.
Consequently, the use of machine learning techniques have been explored in healthcare. Their
ability to help solve diagnostic and prognosis problems has been increasingly exploited.
The main contribution of this work is a prediction tool of survival of patients with cancer
of the colon and/or rectum, after treatment and a few years after treatment. The character-
istics that distinguishes it is the balance between the number of required inputs and their
performance in terms of prediction. The tool is compatible with mobile devices, includes
a online learning component that allows for automatic recalculation and flexibly of the
prediction models, by adding new cases.
The tool aims to facilitate the access of healthcare professionals for instruments that
enrich their practice and improve their results. This increases the productivity of healthcare
professionals, enabling them to make decisions faster and with a lower error rate.
iii

R E S U M O
A importaˆncia de fazer previso˜es na a´rea da sau´de esta´ sobretudo ligada ao processo de
tomada de decisa˜o. Fazer previso˜es de sobreviveˆncia de forma precisa e´ uma tarefa muito
difı´cil para os profissionais de sau´de e uma grande preocupac¸a˜o para os pacientes. Por um
lado, pode ajudar os me´dicos a decidir entre cuidados paliativos ou outra pra´tica me´dica
para um paciente. Por outro lado, a noc¸a˜o do tempo de vida remanescente poderia ajudar
os pacientes na concretizac¸a˜o de sonhos. No entanto, este tipo de previsa˜o esta´ diretamente
relacionada com a experieˆncia do profissional de sau´de e da sua capacidade de memorizar.
A maior parte das deciso˜es sa˜o tomadas com base em probabilidades e estatı´stica, mas
estas teˆm como base grandes grupos de pessoas, podendo na˜o ser adequadas para prever
o que vai acontecer em casos particulares. Por conseguinte, a utilizac¸a˜o de te´cnicas de
machine learning teˆm sido exploradas na a´rea da sau´de. A sua capacidade para ajudar a
resolver problemas de diagno´stico e progno´stico tem sido cada vez mais explorada.
A principal contribuic¸a˜o deste trabalho e´ uma ferramenta de previsa˜o da sobrevida de
pacientes com cancro do co´lon e/ou do reto, apo´s o tratamento e alguns anos apo´s o trata-
mento. As caracterı´sticas que a distingue sa˜o o equilı´brio entre o nu´mero de entradas
necessa´rias e o seu desempenho a nı´vel da previsa˜o. A ferramenta, compatı´vel com dispos-
itivos mo´veis, possui uma componente de aprendizagem em tempo real que permite recal-
cular de forma automa´tica e evolutiva os modelos usados para fazer a previsa˜o, atrave´s da
adic¸a˜o de novos casos.
A ferramenta tem como propo´sito facilitar o acesso dos profissionais de sau´de a instru-
mentos capazes de enriquecer a sua pra´tica e melhorar os seus resultados. Esta aumenta
a produtividade dos profissionais de sau´de, permitindo que estes tomem deciso˜es mais
rapidamente e com uma taxa de erro menor.
v
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I N T R O D U C T I O N
Health care professionals are confronted daily with new diseases, new therapeutics, quick
decisions and cost reductions. At the same time, technology has an increasingly important
role in answering these challenges by finding new solutions, supporting health care profes-
sionals in the course of their duties, assisting with tasks of data and knowledge manipula-
tion, testing new treatments, simulating scenarios, and developing new devices.
This dissertation discloses and assistive tool to help physicians improve their practice.
The problem it addresses is predicting the survival of Colorectal Cancer (CRC) patients (in
an individualized manner). The knowledge upon which the features of the tool are based
was drawn from a large volume of collected data from patients.
This chapter provides a deeper understanding about CRC and the motivation, objectives,
methodology and research behind this dissertation.
1.1 preliminary notions
1.1.1 Anatomy and Physiology of the Digestive System
The cell is the basic unit of life. It is the smallest unit capable of all of the processes that
define life. A cell grows and divides into new cells, in order to ensure the proper body
functions, replacing worn out or injured cells. If a damaged cell is not repaired or does
not die, it continues to grow and forms new abnormal cells. When a cell grows out of
control and invades other tissues it is called a cancer cell. These cells can break away and
travel to other parts of the body through the bloodstream or the lymph system, growing
and forming new tissues there. This spread of cancer to new areas of the body is called
metastasis.
The digestive system (Figure 1) consists of the digestive tract and its accessory organs
(such as the teeth), where food is processed into molecules that can be absorbed to give
the body cells the energy and other substances they need to operate. The digestive tract,
also known as the gastrointestinal tract, consists of a long continuous tube that begins at
1
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the mouth, includes the pharynx, esophagus, stomach, small intestine, large intestine, and
ends at the anus [7, 87].
Figure 1.: Organs of the digestive system [95].
The colon is the most extensive part of the large intestine, also known as bowel. Its
function is to absorb water and nutrients from the food matter and to serve as a storage
place for waste matter. As shown in Figure 2, the colon has 4 parts. The first section is
the ascending colon. It starts with a small pouch (the cecum), where the small intestine
joins the colon, and it extends upward on the right side of the abdomen. The second part
is called the transverse colon, as it goes across the body from the right to the left side in
the upper abdomen. The third section, called the descending colon, continues downward
on the left side. Finally, the fourth and last part is known as the sigmoid colon because for
its ”S” or ”sigmoid” shape. After going through the colon, the material that is left is called
feces or stool. The material enters the rectum, where it is stored until it is expelled of the
body through the anus [6].
The wall of the colon and rectum (Figure 3) is made up of several layers: the mucosa
(or mucous membrane), the submucosa,the muscularis (or muscularis propria), and the
adventitia (or serosa). The mucosa is the innermost layer of the digestive tract that is in
direct contact with digested food. Its layers are responsible for most of digestion, absorptive
and secretory processes, and also for passing waste matter. The submucosa consists in a
dense irregular layer of connective tissue that contains fibroblasts, mast cells, blood and
lymphatic vessels, and a nerve fiber plexus. The muscular layer is the main responsible
for the contractility. It consists of an inner circular layer that prevents food from traveling
backward, and a longitudinal outer layer that shortens the tract. Finally, the serosa forms
the outermost layer of the gastrointestinal tract. It consists of several layers of connective
tissue and secretes a fluid in order to lubricate the surface of the large intestine, defending
2
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Figure 2.: The large intestine [6].
it from the friction between abdominal organs and the surrounding muscles and bones of
the trunk [87].
Figure 3.: The layers of the bowel wall [1].
1.2 the colorectal cancer
1.2.1 Incidence
The most common cancer of the digestive system is CRC, also known as bowel cancer.
It is a term for cancer that starts in the colon or rectum. About 70 percent of the CRC
cases occur in the colon and about 30 percent in the rectum [95]. According to the latest
worldwide cancer statistics (2012), the CRC is the third most frequent cancer worldwide
(Figure 4a) and the fourth deadliest (Figure 4b), for both sexes. Almost 55% of the cases
3
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occur in more developed regions. As shown in Figure 5, the highest estimated rates are
in Australia and New Zealand and the lowest are in Western Africa. CRC mortality is low
when compared to other cancers (694,000 deaths, 8.5% of the total) and the majority of CRC
deaths occurs (52%) in the less developed regions of the world. It is estimated that, in 2020,
the world will have 1.7 million new CRC cases and almost 855 thousand CRC deaths [29].
(a)
(b)
Figure 4.: Estimated cancer incidence and mortality worldwide in 2012, for both sexes [29].
Most CRCs begin as a small growth called a polyp (Figure 6). This growth is a benign
tumor and not all can become into cancer. It starts in the inner lining of the colon or rectum
and grows toward the center, and this process can take many years. Taking out a polyp
early, when it is small, may keep it from becoming cancer [95].
More than 95% of all large bowel tumors are adenocarcinomas (tumors which start in the
gland cells in the lining of the bowel wall). The gland cells produce mucus to lubricate the
inside of the colon and rectum (that makes it easier for the stool to pass through the bowel).
Other rare types include lymphoma and squamous cell carcinoma [1].
4
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Figure 5.: Estimated cancer age-standardised rates worldwide in 2012, per 100.000 people
[29].
The exact cause of CRC is unknown. However, at least eight different genes can be traced
to dietary fat, particularly animal fat [95].
The risk of CRC increases with age. Individuals with a personal or family history of CRC
or polyps, inherited CRC syndromes (i.e., familial adenomatous polyposis and hereditary
nonpolyposis CRC), and patients with ulcerative colitis or Crohn’s disease are at higher risk,
and thus may require screening at an earlier age than the general population. Modifiable
factors associated with increased risk include a diet high in fat and red or processed meat,
but low in fiber, low calcium intake, high caloric intake, physical inactivity, and obesity.
In addition, smoking and excessive alcohol intake may play a role in CRC development
[95, 4, 57].
5
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Figure 6.: Polyps in the colon: some polyps have a stalk and others do not (the photo in the
figure shows a polyp with a stalk) [57].
1.2.2 Symptomatology and Screening
Symptoms may include blood seen in the stool (can be bright red or very dark), unex-
plained persistent constipation alternating with diarrhea, changes in the diameter of stool,
intermittent abdominal pain and the feeling of inadequate emptying of the bowel [95, 4, 57].
CRC can largely be prevented by the detection and removal of adenomatous polyps
(precancerous polyps). From 2006 to 2007, the American Cancer Society, the US Multi So-
ciety Task Force on Colorectal Cancer (a consortium representing the American College of
Gastroenterology, the American Society of Gastrointestinal Endoscopy, the American Gas-
troenterological Association, and the American College of Physicians), and the American
College of Radiology came together to develop consensus guidelines for CRC screening. In
a range of options for CRC screening, the guidelines distinguish between two general cat-
egories, according to current technology: stool tests – which include tests for occult blood
or exfoliated DNA – and structural exams – which include flexible sigmoidoscopy (FSIG),
colonoscopy, double-contrast barium enema (DCBE), and computed tomographic colonog-
raphy (CTC) [51]. The screening tests recommended for CRC screening in men and women
aged 50 or older at average risk are summarized in Table 1 (the complexity involves patient
preparation, inconvenience, facilities and equipment needed, and patient discomfort) [90].
1.2.3 Staging
Cancer staging is the process of finding out how widespread a cancer is, determining
how much cancer is in the body and where it is located. Staging describes the severity
of a individual’s cancer based on the size and/or extent of the original (primary) tumor
6
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Table 1.: Recommendations for CRC screening [90].
Test Benefits Performance & Complexity Limitations Test Time Interval
Flexible Sigmoidoscopy
Fairly quick;
Few complications;
Minimal bowel preparation;
Minimal discomfort;
Does not require sedation
or a specialist.
Performance: High for rectum &
lower one-third of the colon;
Complexity: Intermediate
Views only one-third of colon;
Bowel preparation needed;
Cannot remove large polyps;
Small risk of infection or bowel tear;
Slightly more effective when combined
with annual fecal occult blood testing;
Colonoscopy necessary if abnormalities
are detected.
5 years
Colonoscopy
Examines entire colon;
Can biopsy and remove
polyps;
Can diagnose other
diseases;
Required for abnormal
results from all other tests.
Performance: Highest;
Complexity: Highest.
Can miss some polyps and cancers;
Full bowel preparation needed;
Can be expensive;
Sedation of some kind usually needed,
necessitating a chaperone;
Patient may miss a day of work;
Highest risk of bowel tears or infections
compared to other tests.
10 years
Double-contrast
Barium Enema
Can usually view entire
colon;
Few complications;
No sedation needed.
Performance: High;
Complexity: High.
Can miss some small polyps and cancers;
Full bowel preparation needed;
Cannot remove polyps;
Exposure to low-dose radiation;
Colonoscopy necessary if
abnormalities are detected.
5 years
Computed Tomographic
Colonography
Examines entire colon;
Fairly quick;
Few complications;
No sedation needed;
Noninvasive.
Performance: High;
Complexity: Intermediate.
Can miss some polyps and cancers;
Full bowel preparation needed;
Cannot remove polyps;
Exposure to low-dose radiation;
Colonoscopy necessary if
abnormalities are detected.
5 years
Fecal Occult Blood Test
No bowel preparation;
Sampling is done at home;
Low cost;
Noninvasive.
Performance: Intermediate
for cancer;
Complexity: Lowest.
May require multiple stool samples;
Will miss most polyps and some cancers;
Higher rate of false-positives than other tests;
Pre-test dietary limitations;
Slightly more effective when combined
with a flexible
sigmoidoscopy every five years;
Colonoscopy necessary if
abnormalities are detected.
Annual
Stool DNA Test
No bowel preparation;
Sampling is done at home;
Requires only a single
stool sample;
Noninvasive.
Performance: Intermediate
for cancer;
Complexity: Low.
Will miss most polyps and some cancers;
High cost compared to other stool tests;
New technology with uncertain
interval between testing;
Colonoscopy necessary if
abnormalities are detected.
Uncertain
and whether or not cancer has spread in the body [95]. It is performed for diagnostic and
research purposes, and to help the doctor plan the appropriate treatment. It also gives a
common terminology for evaluating the results of clinical trials and comparing the results
of different trials. On the one hand, if the stage is based on the results of the physical
exam, biopsy, and any imaging tests, it is called a clinical stage. On the other hand, when
it is performed a surgery or biopsy, the results can be combined with the factors used for
the clinical stage, determining the pathologic stage. A cancer is always referred to by the
stage it was given at diagnosis, even if it gets worse or spreads. The survival statistics and
information on treatment by stage for specific cancer types are based on the original cancer
stage at diagnosis.
One of the most widely used cancer staging systems is the TNM (for tumors/nodes/metas-
tases) system, from the American Joint Committee on Cancer (AJCC). It is based on the size
and/or extent of the primary tumor (T) – see Figure 7 –, the amount of spread to nearby
lymph nodes (N), and the presence of metastasis (M) or secondary tumors formed by the
spread of cancer cells to other parts of the body. The TNM system assigns a number to
7
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each letter to indicate the size and/or extent of the primary tumor and the degree of cancer
spread. It is worth noting that each cancer type has its own classification system: letters
and numbers do not always mean the same thing for every kind of cancer. Table 2 shows
all the definitions for T, N, and M.
Figure 7.: The degree of invasion of the intestinal wall [15].
By combining the TNM information, it is possible to obtain an overall “Stage”. It is
expressed in roman numerals: from stage 0 (the least advanced) to stage IV (the most ad-
vanced), as shown in Figure8. These stages can be subdivided using letters, as for instance
IIIA and IIIB.
Figure 8.: Grouping of TNM classification for colorectal cancer.
In addition to the TNM staging system, there are other common staging schemes in use.
The Dukes’ staging classification was originally published by Cuthbert E. Dukes in 1932 for
rectal cancer only and does not include distant metastases. In 1949 it was adapted by Kirklin
and later (in 1953) by Astler and Coller for colon and rectum. To include stage for unre-
sectable tumors and distant metastases, it was revised by Turnbull in 1967. Astler-Coller
8
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Table 2.: Classification of colorectal cancers according to local invasion depth (T stage),
lymph node involvement (N stage), and presence of distant metastases (M
stage) [26].
Primary Tumor (T)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria
T1 Tumor invades submucosa
T2 Tumor invades muscularis propria
T3 Tumor invades through the muscularis propria into the pericolorectal tissues
T4a Tumor penetrates to the surface of the visceral peritoneum
T4b Tumor directly invades or is adherent to other organs or structures
Regional Lymph Nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in 1-3 regional lymph nodes
N1a Metastasis in one regional lymph node
N1b Metastasis in 2-3 regional lymph nodes
N1c Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized
pericolic or perirectal tissues without regional nodal metastasis
N2 Metastasis in four or more regional lymph nodes
N2a Metastasis in 4-6 regional lymph nodes
N2b Metastasis in seven or more regional lymph nodes
Distant Metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
M1a Metastasis confined to one organ or site
(eg, liver, lung, ovary, nonregional node)
M1b Metastases in more than one organ/site or the peritoneum
and Turnbull stagings are also sometimes called Dukes or modified Astler-Coller (MAC)
[95]. It is possible to observe in Table 3 that these staging systems and the correspondence
between them.
Treatment for CRC depends on several factors, including the type and stage of cancer.
Early stages of CRC are often treated with surgery – 95% of Stage I and 65-80% of Stage II
–, extracting the cancer from the colon, rectum or even in other organs in the body where
the cancer has spread to. Radiation therapy, i.e., applying high-energy x-rays to destroy
cancer cells, may be required to minimize the recurrence risk in rectal cancer. Other types
of treatment that are often used are chemotherapy or targeted therapy. Chemotherapy is a
type of cancer treatment that uses medication (chemicals) to neutralize cancer cells, usually
by stopping the ability that cancer cells have to grow and divide. These chemicals can be
9
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Table 3.: Anatomic Stage/Prognostic Groups, seventh edition [26, 42, 35].
Stage T N M Dukes MAC
0 Tis N0 M0 - -
I T1 N0 M0 A A
T2 N0 M0 A B1
IIA T3 N0 M0 B B2
IIB T4a N0 M0 B B2
IIC T4b N0 M0 B B3
IIIA T1-T2 N1/N1c M0 C C1
T1 N2a M0 C C1
IIIB T3-T4a N1/N1c M0 C C2
T2-T3 N2a M0 C C1/C2
T1-T2 N2b M0 C C1
IIIC T4a N2a M0 C C2
T3-T4a N2b M0 C C2
T4b N1-N2 M0 C C3
IVA Any T Any N M1a D D
IVB Any T Any N M1b D D
injected into a vein or given by mouth, injected directly into an artery leading to a part of the
body containing a tumor or can even given directly into the hepatic artery. Targeted therapy
is also a treatment that uses drugs. However, it is different from traditional chemotherapy.
This treatment has as targets the specific genes of the cancer, proteins, or surrounding
tissues that contribute to the cancer growth and survival. Targeted therapy typically has
less severe side effects. It could be used either along with chemotherapy or by itself, if
chemotherapy is no longer working. Depending on the stage of the cancer, two or more
types of therapy may be combined at the same time or used sequentially. When cancer
has spread away from the original tumour site (stage IV), most often it cannot be cured.
However, the cancer may be treatable and its growth and symptoms could be managed
[90].
Based on largest population-based cancer registry in the United States, the Surveillance,
Epidemiology, and End Results (SEER) database – provided by the National Cancer Institute –,
from 2005 to 2011, the five- and ten-year relative survival rates, i.e., statistics that compare
the survival of patients diagnosed with CRC with the survival of people in the general
population (with the same age, race, and sex and who have not been diagnosed with cancer),
are 65% and 58%, respectively. Survival rates for CRC depend on multiple factors, they
often include the stage (Figuer 9). When CRC is detected at a localized stage (cancer is
only in the part of the body where it started), the five-year survival is 90.1%. If the cancer
has spread to a different part of the body, to nearby organs or lymph nodes, the five-year
survival drops to 71%. If the disease has spread to distant organs, the five-year survival
10
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rate is 13%. The five-year survival rate for patients who have just one or a few tumors that
have spread (for instance, to the lung or liver), can be improved if surgical removal of these
tumors is able to eliminate the cancer [4].
Figure 9.: 5-Year Relative Survival (from SEER 18 2005-2011, All Races, Both Sexes by SEER
Summary Stage 2000).
1.3 motivation
The term Artificial Intelligence (AI) was coined be Jon McCarthy in 1956. He defined it
as “the science and engineering of making intelligent machines” at a conference at the
campus of Dartmouth College. This science, when used in medical applications, is called
Artificial Intelligence in Medicine (AIM). The earliest work in AIM dates to 15 years after AI
was founded [66, 93]. Called “The DENDRAL Project”, it was a cooperative work, which
brought together computer scientists, chemists, geneticists and philosophers of science, to
show the capacity to represent and apply expert knowledge in symbolic form [53].
The ability to learn is viewed as the typical characteristic of an intelligent being. Conse-
quently, to develop devices that can get skills from experiences has been one of the driving
ambitions of AI. Machine Learning (ML) is another core part of AI. Its developments have
resulted in a set of techniques which have the potential to alter the way in which knowledge
is created [20, 62].
Data mining is defined as the automatic search, in large amounts of data, for patterns.
It is also known as knowledge-discovery in databases and uses computational techniques
from statistics, ML and pattern recognition.
Medicine is the practice of the diagnosis, treatment and prevention of disease, and the
promotion of health. It is a critical area where the time can be crucial. For shortage of
time, most medical decisions are based on quick judgments and depend on the memory
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of the physician [93]. Training and recertification procedures may improve the physician
skills, encouraging him to keep more of the relevant information in mind [23, 24]. How-
ever, fundamental limitations of human memory and recall mechanisms, coupled with the
exponential growth in knowledge, mean that most of what is known cannot be seized by
most individuals. To overcome this situation, by helping to organize, store, and retrieve ap-
propriate medical knowledge needed, some new areas emerged, namely eHealth, Clinical
Decision Support Systems, Computer-Interpretable Guidelines and Reasoning under Un-
certainty [63, 61, 52]. Some of these technologies are able to suggest appropriate diagnostic,
prognostic and therapeutic decisions.
Accurate prediction of survival is one of the most interesting and challenging tasks for
physicians and it is important for various purposes, such as medical decision making, pa-
tient counselling and benchmarking [49, 99, 16]. The level of physician experience to esti-
mate the survival might affect how prognostic is formulated. However, even an experienced
oncologist has difficulty to predict accurately survival time of a patient with cancer [94].
Survival statistics could help estimate the prognosis of patients, but they are based on
large groups of people, they cannot be used to predict exactly what will happen to an
individual patient [58]. Kaplan-Meier is one of most frequently used method in the conven-
tional analysis of survival problems [99]. It is the simplest way of computing the survival
over time, can be calculated for two groups of subjects and it involves the computing of
probabilities of occurrence of event (death) at a certain point of time [34].
In order to exploit the implied knowledge in large clinical datasets, some sophisticated
modeling in AI approaches to medical reasoning have been exploited through ML tech-
niques [93]. These techniques have competence to discover and identify patterns and the
relationships between them, from complex datasets [49]. Based on this, herein the develop-
ment of a survival prediction model is proposed for CRC patients. To develop the predic-
tion model, ML will be used to discover the relationships between the different variables
and their weights in survival prediction. Approaching of the mobile health (mHealth), the
model will be available in different platforms (smartphones and tablets) and it will target
health care professionals. The developed tool will employ current technologies related with
web development, ubiquitous computing and intelligent interfaces.
1.4 objectives
This dissertation project has the main goal of developing a model to predict the survival
of patients with colon and rectal cancer. Several points were delineated to achieve an
appropriate solution able to help physicians improve their practice, such as:
1. Employ machine learning techniques to process the collected information of CRC
patients from a database;
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2. Construct an accurate model able to predict the survival at 1-, 2-, 3-, 4- and 5-years
after the diagnosis and treatment;
3. Construct an accurate model able to predict the conditional survival at patients who
had already survived at 1-, 2-, 3- and 4-years after the diagnosis and treatment;
4. Find the most relevant features to construct the models through a feature selection
process by a software;
5. Compare the features selected by a software with the features that physicians consider
most relevant;
6. Ascertain whether characteristics used to predict the survival for colon and rectal
cancer patients are the same;
7. Determine if the existing models are effective and are available to health care profes-
sionals to evaluate the developed models;
8. Develop a cross platform mobile to make available the models to health care profes-
sionals;
9. Construct an online learning service to recalculate the models after several entries in
the application.
1.5 document structure
The present work is constituted by six chapters, structured as follows:
INTRODUCTION In the first chapter are introduced important concepts to the comprehen-
sion of all the work. Is made a description of the disease and the work is framed. The
motivation, objectives and document structure are presented.
STATE OF THE ART The second chapter contains the actual solutions for prediction of surviv-
ability in colorectal cancer patients. It presents the survivability prediction tools, for
colon and rectal cancer, and prediction models which are not available in any form to
users. A discussion of the state of the art is made at the end.
DEVELOPMENT OF THE PREDICTION MODEL The third chapter, is the main chapter of the dis-
sertation. It describes all the processes of development of the prediction model, from
the raw data to modeling and evaluation, including the testing phase.
EXPERIMENTAL RESULTS The fourth chapter reveals the results from the development of the
prediction model. All the developed survival and conditional survival models, for
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colon and rectal cancer patients, are compared using metrics and the best models are
selected to embed a prediction tool. A discussion is made at the end of the chapter.
DEVELOPMENT OF AN APPLICATION The fifth chapter describes the processes of development
of an application, in order to make available the models to physicians. The gathering
of functionals requirements and non-functionals requirements is made. Also, the
architecture and the interface of the tool is shown and a use case is made.
CONCLUSIONS AND FUTURE WORK Finally, the sixth and last chapter of this dissertation syn-
thesizes all the accomplished work and the main conclusions from it. A prospect for
future work is mentioned.
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S TAT E O F T H E A RT
In this chapter the most relevant related work within the context of this thesis is presented.
It is separated in two main sections: one for Colon Cancer (CC) and another for Rectal Cancer
(RC). In each of the main sections a review of the current tools to predict the survival in
patients with CC or RC is made. In the section regarding colon cancer, are also reported
some survival models developed, for these cancers, which are not available in any form to
users. Ultimately, in a third section, is made a discussion of the state of the art.
2.1 survivability prediction tools
2.1.1 For Colon Cancer
Bush and Michaelson (2009)
The CancerMath.net group – a section of the Laboratory for Quantitative Medicine from
Massachusetts – developed a series of web-based calculators1 for accurately predicting the
clinical outcome for individual cancer patients. These tools are available for melanoma,
breast, renal, colon, head and neck cancers.
The CC outcome calculator is a work in progress and it was reported by Bush and
Michaelson [14]. This tool provides information on survival expectation at the time of
diagnosis, for each of the first 15 years after diagnosis. Also provided is the life expectancy
with and without cancer, and the reduction of life expectancy caused by cancer.
The data used to developed the CC tool was extracted from the SEER dataset, from 1973
to 2006.
The variables used to construct the model were: the age of the patient at diagnosis,
gender (male or female), tumor diameter (in cm), number of positive nodes, carcinoembry-
onic antigen (CEA)2 status (positive or negative), histological type, grade (well differenti-
ated, moderately differentiated, poorly differentiated or undifferentiated), site (region of
1 This tool is available at http://www.lifemath.net/cancer/coloncancer/outcome/index.php.
2 CEA is a glycoprotein and is used as a tumor marker. In increased large are associated with adenocarcinoma,
especially colorectal cancer.
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the colon) and farthest tumor extension. Through the information of farthest tumor exten-
sion and number of positive nodes, this tool can provide the TNM classification and AJCC
stage group.
Nodes + Prognostic Factors (NAP) method was created to more accurately model the CC
lethality based on the number of positive nodes, combined with prognostic factors. The
NAP method is written below, in equations (1), (2) and (3). The prognostic factors are
represented by (g1, g2, g3, . . . , gn). Q, R and jprimary are empirically derived constants.
Lprimary = 1− e(−Q∗(g1∗g2∗g3∗. . . ∗gn)∗jprimary) (1)
Lnodes = 1− e(−R∗(# positive nodes)) (2)
Loverall = Lprimary + Lnodes–(Lprimary ∗ Lnodes) (3)
For the CC model, the jprimary constant of 0.61299589 was only applied to tumors with
zero known positive nodes. For tumors with any positive nodes, or unknown positive
nodes, the jprimary is 1.
Figure 10 shows that the 3-, 5- and 15-year Kaplan-Meier disease-specific death rates. It
shows an approximately 25% reduction in deaths, from the 1970s to 2003.
Figure 10.: Disease-specific Kaplan-Meier lethality by year (from 1973 to 2003) [14].
The interface of this tool is shown in Figure 11. No performance results are known for
this tool.
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Figure 11.: Web-based calculators for accurately predicting the clinical outcome for individ-
ual colon cancer patients and results [13].
Chang et al. (2009)
From The University of Texas M. D. Anderson Cancer Center, Chang et al. [18] created
a browser-based calculator3 to predict individualized disease-specific survival and condi-
tional survival4.
By utilizing data from the SEER registry, 83,419 patients with colon adenocarcinoma
diagnosed between 1988 and 2000 were analyzed.
The variables used to develop the model were: age of the patient at diagnosis (categorized
into age less than 50 years, 50 to 59 years, 60 to 69 years, 70 to 79 years and ≥ 80 years),
gender (male or female), ethnicity (white, black or other), tumor grade (well differentiated,
moderately differentiated, and poorly differentiated or undifferentiated) and AJCC sixth
edition stage group. The inclusion of the SEER region, year of diagnosis, marital status
3 The browser-based conditional survival calculator is available at http://www3.mdanderson.org/coloncalculator.
4 The survival probability calculated after a given length of survival, including only individuals who have sur-
vived to a predefined time of interest.
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and tumor location was also tested, but these features did not improve model performance
or prediction accuracy. A multivariate Cox regression analysis was performed by using
the Breslow method for ties to evaluate the simultaneous effect of multiple variables on
survival.
The Kaplan-Meier unadjusted (10-year) disease-specific survival probabilities for patients
diagnosed with CC stratified by AJCC stage (sixth edition) is shown in Figure 12.
Figure 12.: Unadjusted AJCC disease-specific survival for patients with CC who were diag-
nosed between 1988 and 2000 [18].
The conditional survival was applied to obtain a more accurate survival probability. It is
utilized especially when the initial prognosis is poor. Conditional survival estimates were
calculated by using the multiplicative law of probability after adjustment for variables. The
Concordance Index (C-index) of this implementation was 0.816.
Figure 13 shows the interface of this tool and Figure 14 shows the results.
Weiser et al. (2011)
From Memorial Sloan Kettering Cancer Center, Weiser et al. [104] developed a tool5
with the ability to predict the overall survival probability of the CC patient at least five
years following surgical removal of all cancerous tissue.
The tool can produce three different estimates based on the amount of data included, and
the accuracy increases with the amount of submitting information. For that purpose, three
nomograms using multivariable regression with Cox proportional hazards modeling were
created. This tool also provides a highly likely range for the probability of survival, known
as the 95% confidence interval.
5 This tool is available at https://www.mskcc.org/nomograms/colorectal/overall-survival-probability.
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Figure 13.: Browser-based calculator to predict individualized disease-specific survival and
conditional survival for colon cancer patients [17].
Figure 14.: Results of the browser-based calculator to predict individualized disease-specific
survival and conditional survival for colon cancer patients [17].
To construct and validate the three survival models the records from 128,853 primary
colon cancer patients reported to the SEER from 1994 to 2005 were applied.
For a basic estimate of overall survival probability it is necessary to know the depth of
tumor penetration into the colon wall (T stage) and the N stage, according to the TNM
anatomic staging system, introduced in Section 1.1. For a more accurate estimate, it is nec-
essary to know T stage, the number of positive lymph nodes (value between 0 and 16) and
the number of total lymph nodes (value between 0 and 45). For the most accurate estimate,
in addition to the data required in the previous accurate estimate, it vital know the age of
the patient at the time of surgery, gender (male or female) and tumor differentiation/grade
(poor, moderate or well differentiated).
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All these variables were chosen a priori on the basis of their well-established independent
associations with overall survival and their availability in the SEER registry.
Kaplan-Meier overall survival curves for the entire population, according to the AJCC
classification schema (seventh edition), are shown in Figure 15.
Figure 15.: Kaplan-Meier overall survival on the basis of the seventh edition of the AJCC
Staging Manual [104].
The simplest nomogram, based only on T and N elements, presented the minor C-index,
with 0.61 (95% CI, 0.60 to 0.62). It was followed by the model that includes the number of
lymph nodes examined and number of metastatic lymph nodes examined, with 0.63 (95%
CI, 0.62 to 0.64). Finally, the highest C-index belongs to the model including the pathologic
tumor differentiation and demographic variables of age and gender, with 0.68 (95% CI, 0.67
to 0.68). The Receiver Operating Characteristic (ROC) curves for the extended model had
higher sensitivity, at all values of specificity, than the TNM system and calibration curves
indicated no deviation from the reference line.
The interface of this tool is shown in Figure 16 and the results in Figure 17.
Renfro et al. (2014)
From Mayo Clinic, Renfro et al. [86] created a clinical calculator6 for overall survival and
time to recurrence for stage III colon cancer. It was developed in order to obtain predicted
probabilities of being recurrence-free at three years and alive at five years over the start of
treatment, with confidence intervals.
Multivariable Cox proportional hazards models for overall survival and time to recur-
rence were formulated using data from 15,936 stage III CC patients. These data were col-
6 This clinical calculator is available for use at http://www.mayoclinic.org/medical-professionals/cancer-
prediction-tools/colon-cancer.
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Figure 16.: Colorectal cancer nomogram: overall survival probability [103].
Figure 17.: Results of colorectal cancer nomogram [103].
lected from 12 randomized clinical trials, from 1989 to 2002, contained in the Adjuvant Colon
Cancer End Points (ACCENT) database.
Models were constructed using variables such as the age (as continuous variable), sex
(male or female), race (white, black, asian, or other), body mass index (as a continuous
variable), Eastern Cooperative Oncology Group/World Health Organisation performance
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(a) Patient characteristics: first screen. (b) Patient characteristics: second screen.
Figure 18.: Web calculator to predict recurrence and overall survival in stage III colon cancer
[85].
status scale7 [60] (0, 1, 2+), tumor grade (1, 2, 3+), tumor stage (T-stage; T1, T2, T3, T4), ratio
of the number of positive lymph nodes to the number of nodes examined (as continuous
variable, between 0 and 1), number and location of primary tumors (any multiple, single
left, single right, or single transverse/flexures), and treatment class (oral/infusional/bolus
5FU variations vs 5FU with oxaliplatin vs 5FU with irinotecan).
Model for overall survival had a C-index of 0.66. Figure 18 shows the interface of this
tool and Figure 19 its results.
2.1.2 For Rectal Cancer
Wang et al. (2011)
From the OHSU Knight Cancer Institute, Wang et al. [102] developed an interactive tool8
to make an individualized prediction of the conditional survival for a RC patient, after a
certain period of time passed since diagnosis and treatment.
7 Scale developed by the Eastern Cooperative Oncology Group (ECOG), part of the ECOG-ACRIN Cancer Re-
search Group. It describes a patient’s level of functioning in terms of their ability to care for themself, daily
activity, and physical ability (walking, working, etc.).
8 This prediction calculator is available at http://skynet.ohsu.edu/nomograms/gastrointestinal/rectal.php.
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Figure 19.: Results of the web calculator to predict recurrence and overall survival in stage
III colon cancer [85].
The prediction calculator was constructed based on data from 42,830 RC patients who
were diagnosed between 1994-2003, from the SEER 17 database. Conditional survival pre-
diction is calculated from a Cox proportional hazards model.
The primary outcome variable was overall survival conditional on having survived up
to 5 years from diagnosis. Covariates included in the model were age (as a continuous
variable), race (white, black, Asian/Pacific Islander, Alaskan/American Indian), sex, and
stage (AJCC TNM grouped stage from third edition).
The 10-year actuarial survival data (Figure 20) were used to calculate the 5-year observed
conditional survival in categories of stage, age, gender, and race.
The C-indexfor the model of this approach was 0.75. Figure 21 shows a screenshot of this
interactive web-based prediction tool.
Valentini et al. (2011)
From the MAASTRO Clinic, Valentini et al. [98] developed nomograms9 as a tool to
predict the probability that a rectal cancer patient will be alive or will have local recurrence
or distant metastasis after delivery of long-course radiotherapy, with optional concomitant
and/or adjuvant chemotherapy, over a 5-year period after surgery.
Based on Cox regression, multivariate nomograms were developed. They were built
based on 2,795 individual patient data collected from five European randomized trials10 that
tested preoperative chemoradiotherapy against preoperative radiotherapy or postoperative
chemoradiotherapy and adjuvant chemotherapy, between 1992 to 2003.
9 This prediction calculator is available at http://www.predictcancer.org/.
10 Trial name: European Organisation for Research and Treatment of Cancer, Fe´de´ration Francophone de Cance´rologie
Digestive, Working Group of Surgical Oncology/Working Group of Radiation Oncology/Working Group of
Medical Oncology of the Germany Cancer Society, Polish and Italian.
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Figure 20.: 10-year Kaplan–Meier overall survival by stage [102].
Training the Cox model (training data), important predictors for outcome and the vari-
ables that have a significant effect, were selected. The required information for the overall
survival calculator was gender (male or female), age at the date of randomization (as a
continuous variable), clinical tumor stage (1+2, 3 or 4), radiotherapy dose (< 45 Gy, 45 Gy,
and > 45 Gy), surgery procedure (low anterior resection [LAR] or abdominoperineal re-
section [APR]), adjuvant chemotherapy (yes/no), pathological tumor and nodal stage. The
concomittant chemotherapy (yes/no) is used to calculate the local recurrence. However, it
must be inserted, even for overall survival prediction, because it is a field required for the
tool.
Kaplan-Meier curves of risk group stratification for overall survival for dataset validation
can be observed in Figure 22.
The nomogram for overall survival had a C-index of 0.70 (95% CI, 0.65 to 0.74). Figure
23 shows the interface of this tool and Figure 24 exemplifies the results provided by it.
The results of this tool – for instance, the result obtained for a female, 55 years old,
with clinical tumor stage of 3, radiotherapy dose of 45 Gy, no concomittant chemotherapy,
low anterior resection as surgery procedure, no adjuvant chemotherapy, 3 for pathological
tumor stage and 1 for pathological nodal stage –, can be interpreted as would be if a group
of 100 patients with the same characteristics as this individual patient, 67 patients would
have no local recurrence, 50 patients would have no distant metastases, 63 patients would
be alive 5 years after the treatment. Due to the fact that a model can never be completely
the same as the “real world”, these numbers could be lower or higher, but these are the
most likely values. This particular patient has a high risk of developing a local recurrence,
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Figure 21.: Interactive tool for individualized estimation of conditional survival in rectal
cancer and its results [101].
high risk of developing distant metastases and a high risk of dying within 5 years after
treatment.
Bowles et al. (2013)
From The University of Texas M. D. Anderson Cancer Center, Bowles et al. [10] created
an internet-based individualized conditional survival calculator11 for patients with RC.
Taking into account the simultaneous effect of multiple variables on survival, separate
multivariate Cox regression models were built for: no radiotherapy, preoperative radio-
therapy, postoperative radiotherapy and stage IV patients. These models were created to
11 This prediction tool can be accessed at www.mdanderson.org/rectalcalculator.
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Figure 22.: Kaplan-Meier curves of risk group stratification for overall survival for valida-
tion dataset [98].
Figure 23.: Nomograms for predicting local recurrence, distant metastases, and overall sur-
vival for patients with locally advanced rectal cancer [97].
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Figure 24.: Results of the nomograms for predicting local recurrence, distant metastases,
and overall survival for patients with locally advanced rectal cancer [97].
determine adjusted survival estimates (at year 1 through 10) and used to calculate 5-year
adjusted conditional survival. They were constructed using registries of 22,610 patients
with rectal adenocarcinoma, who were diagnosed from January 1988 to December 2002,
from the SEER database.
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Models developed for patients with localized stage (stage I-III), i.e., for patients who un-
derwent no radiotherapy, preoperative radiotherapy or postoperative radiotherapy, covari-
ates were the same. They included age (<50, 50-59, 60-69, 70-79, 80+), sex (male, female),
race (white, black, other), tumor grade (low [well-differentiated, moderately-differentiated],
high [poorly-differentiated or undifferentiated] or unknown), surgery type (local excision
and radical surgery) and AJCC sixth edition stage. In the model built for stage IV patients,
i.e., for patients with distant metastasis, the surgery type was treated as a binary variable
in the model (using any radiotherapy or primary tumor directed surgery as covariates).
The measures of performance for this tool are not available. Figure 25 shows the interface
of this tool and Figure 26 its results for no radiotherapy. The other models are available
clicking on the links shown in the figure.
Figure 25.: Browser-based calculator to predict individualized disease-specific survival and
conditional survival for rectal cancer patients [9].
2.2 prediction models
Snow et al. (2001)
Snow et al. [89] developed an Artificial Neural Network (ANN) model and a regression-
based model to predict individual patient survival status 5 years after treatment.
Both models were developed employing 37,500 registries of colon carcinoma patients,
from the National Cancer Data Base (NCDB), United Kingdom. The data used were collected
from 1985 to 1993.
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Figure 26.: Results of the browser-based calculator to predict individualized disease-specific
survival and conditional survival for rectal cancer patients [9].
ANNs were applied to select the more important variables from the NCDB. This method
was chosen in virtue of the ANN abilities to find patterns in complex data, with many
variables. The logistic regression was used because of its widespread acceptance by bio-
statistians as a standard for prediction. Both methods were compared on a prospective set
of patients that were not included in model development.
A sensitivity analysis method was used and the variables that resulted in significant
loss of accuracy were dropped. As a result, the gender, age, number of positive regional
lymph nodes, number of regional lymph nodes examined, pathologic T, N and M code of
TNM, pathologic AJCC stage group, residual tumor (none, microscopic or macroscopic), if
surgery was performed and if radiation therapy was performed were the selected variables
to incorporate in the model. Figure 27 shows the ANN used in this analysis.
Figure 27.: ANN used in the analysis [89].
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Figure 28 shows the survival stratified by pathologic Dukes stage in the NCDB database.
The survival plot is a Kaplan–Meier type and uses a Cox model.
Figure 28.: Survival plot stratified by pathologic stage. Letters A, B, C, and D refer to Dukes
Stages [89].
The area under the ROC curve was used to measure the overall predictive accuracy of
the network. The ANN yielded a ROC area of 87.6%. A sensitivity to mortality of 95%, the
specificity was 41%. The logistic regression provided a ROC area of 82%, and sensitivity to
mortality of 95% gave a specificity of only 27%.
Stojadinovic et al. (2012)
Stojadinovic et al. [92] created a clinical decision support system using a Machine-Learned
Bayesian Belief Network (ML-BBN) model for real-time estimation of overall survival in CC,
providing personalized estimates of survival among patients.
A ML-BBN is a hierarchical network of associations between clinical factors in a registry
data set that supplies multivariate mapping of complex data, allowing users to understand
how different features are conditionally independent of each other [92, 91]. ML technology
was employed because of its capability to capture complex, nonlinear, and in some cases,
non-obvious patterns in a very large and heterogeneous data set.
The ML-BBN was constructed based on data from 146,248 records of patients with CC
diagnosed between 1969 and 2006, from the SEER registry. From each registry independent
prognostic factors were analyzed, including age and race of patient, the primary histology,
grade and location of tumor. The number of primaries, AJCC T stage, N stage, and M stage
were also considered.
Survival cohorts were developed based on follow-up time and overall survival time. To
evaluate overall survival at different clinically relevant time points 4 subsets were created
based on follow-up times of 12, 24, 36, and 60 months.
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Models were compared with one another and with the AJCC TNM system by calculating
a C-index, performing calibration, and identifying the area under ROC curves. Table 4
details these results. To validate the models, a Kaplan-Meier analysis was performed us-
ing the estimated mortality probabilities produced by the BBN as an additional validation
method.
Table 4.: Comparative performance statistics – AJCC TNM Staging (Sixth Edition) vs. ML-
BBN [92].
Mortality
AUC PPV NPV Sensitivity Specificity
AJCC BBN AJCC BBN AJCC BBN AJCC BBN AJCC BBN
12 months 0.75 0.85 36.2 % 74.4 % 88.7 % 85.1 % 36.2 % 51.4 % 88.6 % 94.0 %
24 months 0.76 0.85 54.6 % 79.9 % 81.1 % 79.7 % 54.6 % 62.7 % 81.1 % 90.3 %
36 months 0.77 0.85 67.7 % 81.8 % 72.2 % 73.9 % 67.7 % 69.9 % 72.2 % 84.5 %
60 months 0.77 0.85 85.9 % 84.2 % 47.7 % 64.8 % 85.9 % 88.7 % 47.7 % 55.5 %
The results showed that when compared with the AJCC staging system alone, these ML-
BBN models showed superior sensitivity and specificity in estimating mortality. The larger
area under the ROC curves (0.85) of the models shows that the ML-BBNs have a better
discriminatory capacity in estimating survival within a defined period following initial
cancer treatment. The large areas under the ROC curves were further confirmed using
Kaplan-Meier (log rank) analysis that shows high, statistically significant odds ratios.
Al-bahrani et al. (2013)
Al-bahrani et al. [3] developed a survival prediction model for colon cancer, using en-
semble data mining. In this work, supervised classification methods were used to predict
survival of patients, at the end of 1 year, 2 years and 5 years of diagnosis.
The SEER data from 1973 to 2009 was analyzed and passed for a cleanup process, in a
total of 105,133 registries. The original dataset with 134 attributes was reduced to 65, by
removing useless attributes. Three new classes were created for 1 year, 2 years and 5 years
survivability. This distribution of the data is shown in Table 5. After the cleanup process,
there were a total of 65 attributes plus the class.
Table 5.: Class distribution of data [3].
Survival Classes
1 Year 2 Year 5 Year
Not Survived 21.44% 30.44% 42.06%
Survived 78.56% 69.56% 57.94%
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From the 65 attributes, a selection of attributes was performed using Correlation Feature
Selection (CFS) [36] and Information Gain Ratio (IGR), yielding 13 attributes. These selected
attributes and their description can be observed in Table 6.
Table 6.: Selected Attributes.
Attribute Description
EOD-Extension Documented tumor away from the primary site
SEER modified AJCC Stage
3rd ed (1988-2003)
The modified version stages cases that would be unstaged under
strict AJCC staging rules
Birth Place Place of birth encoded
EOD-Lymph Node Involv Highest specific lymph node chain that is involved by the tumor
Regional Nodes Positive Number of regional lymph nodes examined
RX Summ-Surg Prim Site Surgical procedure for remove and/or destroy tissue
Histologic Type ICD-O-3 Microscopic composition of cells and/or tissue for a specific primary
Reason for no surgery Reason that surgery was not performed on the primary site
Age at diagnosis Age of the patient at diagnosis
Diagnostic Confirmation The best method used to confirm the presence of the cancer
EOD-Tumor Size Largest dimension of the primary tumor (millimeters)
Behavior (92-00) ICD-O-2 Behavior codes of the cancer
Primary Site The site in which the primary tumor was originated
The approach compares a model using the 65 attributes, acquired after filtering the data
and removing the useless attributes, with another model using the 13 selected attributes
which were obtained after running feature selection methods. As shown in Table 5, the
dataset was imbalanced. Consequently, in the 13 selected attributes the Synthetic Minority
Over-sampling Technique (SMOTE) was applied to generate synthetic examples by oversam-
pling the minority class and introducing new synthetic patient records. The data that re-
sulted of this process were used to construct another model, which was also compared with
the previous developed models.
The WEKA toolkit was used to construct the models for survival prediction for colon
cancer patients. Different basic and meta classification schemes were tested. The basic
classification algorithms used were the J48 decision tree [69], REPTree [105], Random For-
est [12], ADTree [30] and Logistic Regression [33]. In order to boost the basic classifiers
and improve their performance, the following meta classifiers were used: Bagging [12],
AdaBoost [32], Random Subspace [39] and Voting12 [46].
The ensemble voting, composed by the top 3 performing classification schemes, was the
best model. It had a predictive percentage accuracy of 90.38%, 88.01%, and 85.13% for 1
year, 2 years, and 5 years respectively and an area under the ROC curve of 0.96, 0.95, and
0.92 for 1 year, 2 years, and 5 years respectively.
12 Voting is a popular ensemble technique for combining multiple classifiers.
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2.3 discussion
Throughout the chapter of the state of the art, several models to predict the survival
of colorectal cancer patients were found. Some of them are available to physicians and
patients in a web-based tool.
Table 7 shows the variables used in the applications and models to calculate the survival
of CC patients.
Table 7.: Variables used in the applications and models for colon cancer patients.
Applications Models
Bush and Michaelson
(2009) [14]
Chang et al.
(2009) [18]
Weiser et al.
(2011) [104]
Renfro et al.
(2014) [86]
Snow et al.
(2001) [89]
Stojadinovic et al.
(2012) [92]
Al-bahrani et al.
(2013) [3]
Age 3 3 3 3 3 3 3
Gender 3 3 3 3 3 5 5
Grade 3 3 3 3 5 3 5
Stage 5 grouped stage T- and N-stage T-stage TNM and grouped stage TNM grouped stage
CEA status 3 5 5 5 5 5 5
Race 5 3 5 3 5 3 5
Number of positive nodes 3 5 3 3 3 5 3
Total number of nodes 5 5 3 3 3 5 5
Tumor diameter 3 5 5 5 5 5 3
Histological type 3 5 5 5 5 3 3
Site of the colon 3 5 5 3 5 3 3
Surgery 5 5 5 5 3 5 3
Radiation therapy 5 5 5 5 3 5 5
Residual tumor 5 5 5 5 3 5 5
Number of primaries 5 5 5 3 5 3 5
Extension of tumor 3 5 5 5 5 5 3
Birth place 5 5 5 5 5 5 3
Lymph node involved† 5 5 5 5 5 5 3
Reason for no surgery 5 5 5 5 5 5 3
Diagnostic confirmation 5 5 5 5 5 5 3
Behavior 5 5 5 5 5 5 3
Body mass index 5 5 5 3 5 5 5
Treatment type 5 5 5 3 5 5 5
Performance status 5 5 5 3 5 5 5
† Contained in TNM stage.
Table 8 shows the overall characteristics of models (with and without application avail-
able to users) for CC patients.
Table 8.: Characteristics of models (with and without an application available to users) for
colon cancer patients.
Applications Models
Bush and Michaelson
(2009) [14]
Chang et al.
(2009) [18]
Weiser et al.
(2011) [104]
Renfro et al.
(2014) [86]
Snow et al.
(2001) [89]
Stojadinovic et al.
(2012) [92]
Al-bahrani et al.
(2013) [3]
Number of Variables 9 6‡ 2/3/7 12 9 7 13
Dataset SEER SEER SEER ACCENT NCDB SEER SEER
Model regression-based regression-based regression-based regression-based
ML-based and
regression-based
ML-based ML-based
Target 0 – 15 years
1 – 10 years
(disease specific survival)
0 – 5 years
(conditional survival)
5 years 5 years 5 years 1, 2, 3 and 5 years 1, 2 and 5 years
Performance – C-index: 0.816 C-index: 0.61/0.63/0.68 C-index: 0.66
AUC: 0.876
(ANN)
AUC: 0.82
(logistic regression)
AUC: 0.85
AUC: 0.96/0.95/0.92
Accuracy:
90.38%/88.01%/85.13%
‡ Including months which already survived (for conditional survival calculate).
In a review of literature, none of models without an application for RC patients was
found. Table 9 shows the variables used in the tools for rectal cancer patients.
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Table 9.: Variables used in the applications for rectal cancer patients.
Applications
Wang et al.
(2011) [102]
Valentini et al.
(2011) [98]
Bowles et al.
(2013) [10]
Age 3 3 3
Gender 3 3 3
Grade 5 5 3
Stage grouped stage
clinical T-, pathological T-
and pathological N-stage
grouped stage
Race 3 5 3
Surgery Procedure 5 3 3
Radiotherapy dose 5 3 5
Concomittant chemotherapy 5 3 5
Adjuvant chemotherapy 5 3 5
Table 10 shows the overall characteristics of models with an application available to users
for RC patients.
Table 10.: Characteristics of models (with an application available to users) for rectal cancer
patients.
Wang et al.
(2011) [102]
Valentini et al.
(2011) [98]
Bowles et al.
(2013) [10]
Number of Variables 5‡ 9 7‡
Dataset SEER
five European
randomized trials
SEER
Model regression-based regression-based regression-based
Target 0 – 5 years 1– 10 years
1 – 10 years (disease specific survival)
0 – 5 years (conditional survival)
Performance C-index: 0.75 C-index: 0.70 –
‡ Including months which already survived (for conditional survival calculate).
Observing the variables used to calculate the survival of patients with colon cancer, only
the age of the patient is common to all models (with and without an application available).
The stage of cancer (in grouped form), gender of patient, grade of tumor and the number
of positive nodes are the other common variables. All the tools used to predict the survival
of rectal cancer patients are to calculate the conditional survival and all of them employ
the age and gender of patients. The stage of cancer (in grouped form), race of patient
and surgery procedure are the other common variables. Moreover, the way in which the
variables were selected to be part of model was not always evident. The present work
intends to use data mining techniques to select the most relevant features and compare
them to the opinion of a specialist physician, using the prognostic factors and the relations
between them. Another goal is to know if similar features are selected for both cancers.
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In order to assess the performance of models, all works described herein applied one of
two metrics: the C-index and the The Area Under the ROC Curve (AUC). These measures are
considered to be numerically identical [38]. They correspond to the probability of giving
a correct response in a binary prediction problem. A value of 1 means a perfect model,
whereas a value of 0.5 indicates a random guessing model [43, 44, 54]. According to this,
the model developed by Al-bahrani et al. [3] is the work that had the best perfomance
values for colon cancer survival prediction (with an AUC of 0.96, 0.95 and 0.92, for 1, 2 and
5year, respectivelly). However, this work is not available under any platform to health care
professionals. For rectal cancer survival prediction, the best results known belong to Wang
et al. [102] (with a C-index of 0.75).
All the presented tools utilize regression models. Ahmed et al. [2] compared a regression-
based model with a ML-based model, having obtained better results of performance using
ML. Modeling with ML techniques allows to find underlying patterns and makes possible
to deal with missing information. In this work we intend to develop a model using machine
learning techniques.
To determine if related tools are suitable to mobile devices, all applications (for both
cancers) were analyzed using the mobile-friendly test tool of Google13. The tool of Google
reported all applications, except the ones developed for colon cancer patients by Weiser et
al. [104] and Renfro et al. [86], are unsuitable to access via smartphone or even tablet.
The test revealed that the text was too small to read, the mobile viewport was not set, links
were too close together or content was wider than the screen. Therefore, none of these
applications had a mobile-friendly design. Another goal is to address this and develop a
cross-platform tool, that is available to users in a practical and intuitive way, through a
smartphone or tablet.
13 Mobile-friendly test tool of Google is available at https://www.google.com/webmasters/tools/mobile-
friendly/
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3
D E V E L O P M E N T O F T H E P R E D I C T I O N M O D E L
This chapter is the main of the dissertation. It describes all the processes of the develop-
ment of the prediction model, from the raw data to the modeling and evaluation phase, in-
cluding testing. Prediction models were developed to calculate the survival and conditional
survival of colon and rectal patients after diagnosis and treatment, taking into account the
cover a 5-year span – an important goal for a colorectal cancer patient to overcome. The
conditional survival model was developed applying the methods which produced the best
results for the the survival models.
3.1 raw data importing
The survival prediction systems, for colon and rectal cancer, were projected to produce
an individualized response. Each system was planned to receive a number of inputs for
selected prediction features and, for each of the 5 years following treatment, generate an
output stating whether the patient in question will survive that year or not, along with a
confidence value for the prediction. In case of the conditional survival prediction systems,
the process is similar. Depending on the years that the patient has already survived, the
generated output is given for each following years, until the fifth year after treatment.
The National Cancer Institute provides the access to the largest population-based cancer
database in the United States of America, by the SEER Program. This database contains
8,689,771 cases collected from 1973 to 2012, including several types of cancer. Its registries
are available in the binary format. For that reason, it was required create a script to convert
the relevant dataset into an intelligible form, for later be imported to a data mining software
(Figure 29). The software chosen to develop the prediction model was RapidMiner Studio
(6.5 version)1, an open source data mining software. It has a workflow-based interface that
allows an clear construction of complex data management processes. Moreover, it offers an
intuitive Application Programming Interface (API).
1 Software available at http://rapidminer.com/.
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Figure 29.: From raw data to RapidMiner Studio software.
The development of a prediction model requires several phases, from the preprocessing
of SEER data to the selection of the best model. All of the phases are described in the
ensuing sections. It is important to clarify that the survival prediction was handled as a
classification problem and five classification models, for each year and type of cancer (colon
and rectal), were developed. Theses models were posteriorly combined, in a programmatic
manner, into a model capable of providing a prediction for each year with a single interac-
tion, within the selected cancer type.
3.2 preprocessing
The colorectal cancer data from SEER contained 515,791 records, from 1973 to 2012, and
consisted of 146 attributes, some of them only applicable to a limited period within the time
of data collection.
During the Preprocessing phase, it was defined that the period of interest would be from
2004 onwards, minimizing the occurrence of missing data due to the applicability of the
attributes. This operation was determined filtering [75] the data by the year of diagnosis.
Additionally, empty attributes, attributes that are not applicable to this type of cancer
(e.g., the human epidermal growth factor receptor 2 result, an indicator used in breast
cancer only [106]) and attributes that are not directly related with the vital status of the
patient were removed (e.g. the number identifying the registry of the patient). It was
defined by using the Select Attributes operator [83] and selecting the pertinent attributes.
Only the adult patients (age greater than or equal to 18 years old) were selected for
further processing (filtering [75] by the age of diagnosis) and the missing values were re-
placed (using the Replace Missing Values operator [80] of RapidMiner software) applying
the unknown code.
Patients who were alive at the end of the data collection whose survival time had not
yet reached 60 months (five years), the maximum period for which the model under devel-
opment is supposed to predict survival, and those who passed away of causes other than
colon or rectal cancer were sampled out (filtering by survival months and the cause of death
to SEER site [75]) from the training set as their inclusion was considered to be unsuited to
the problem at hand. The numeric attributes were converted to nominal [77] (e.g. sex) and
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the binary classes (survived and not survived) were derived for the target labels 1-, 2-, 3-, 4-
and 5-year survival.
Finally, based on existing attributes and at the request of a physician who collaborated
in this work, new attributes, such as the number of regional lymph negative nodes, the
ratio of positive nodes over the total examined nodes and also the relapse of the patients
for colon cancer, were calculated. It was defined using aggregate functions [72] and the
Generate Attributes operator [76].
After the Preprocessing phase, the attributes were reduced to 61, including the new at-
tributes and the target labels and the data was reduced to 51,410 records: 38,592 and 12,818
registries, for colon and rectal cancer, respectively. From the isolated cases for each pathol-
ogy, 10% were randomly selected for a testing set and the remaining were used to developed
the prediction models.
3.3 split dataset
For the survival prediction, the second phase consisted in divide the data into five sub-
datasets (for each cancer type). The data was split by target label, according to the cor-
responding survival year. Table 11 and Table 12 shows the class distribution in each sub-
dataset, for colon and rectal cancer, respectively.
Table 11.: Class distribution for each target label in the sub-datasets, for survival models
and colon cancer.
Target Labels
1 Year 2 Year 3 Year 4 Year 5 Year
Not Survived 24.51% 32.60% 36.96% 39.35% 41.07%
Survived 75.49% 67.40% 63.04% 60.65% 58.93%
Total number of cases 34,732
Table 12.: Class distribution for each target label in the sub-datasets, for survival models
and rectal cancer.
Target Labels
1 Year 2 Year 3 Year 4 Year 5 Year
Not Survived 4.03% 5.89% 7.17% 8.08% 8.70%
Survived 87.88% 82.27% 78.41% 75.68% 73.79%
Total number of cases 11,536
For the conditional survival prediction, the data was split into ten datasets (for each type
of cancer). The data were separated by target label, according to the corresponding survival
year and the years that patients had already survived. For instance, taking into account that
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a patient which already survived the first year after treatment, will be necessary calculate
the outcome from the second to fifth year. In this way, registries from patients who died
during the first year were not included of the sub-dataset. Table 13 and Table 14 shows the
class distribution in each sub-dataset, for colon and rectal cancer, respectively.
Table 13.: Class distribution for each target label in the sub-datasets, for conditional survival
models and colon cancer.
Target Labels
survived the 1st year survived the 2nd year survived the 3rd year survived the 4th year
2 Year 3 Year 4 Year 5 Year 3 Year 4 Year 5 Year 4 Year 5 Year 5 Year
Not Survived 11.45% 18.77% 22.30% 24.40% 8.15% 12.15% 14.55% 4.24% 6.84% 2.77%
Survived 88.55% 81.23% 77.70% 75.60% 91.85% 87.85% 85.45% 95.76% 93.16% 97.23%
Total number of cases 15,765 13,969 12,816 12,261
Table 14.: Class distribution for each target label in the sub-datasets, for conditional survival
models and rectal cancer.
Target Labels
survived the 1st year survived the 2nd year survived the 3rd year survived the 4th year
2 Year 3 Year 4 Year 5 Year 3 Year 4 Year 5 Year 4 Year 5 Year 5 Year
Not Survived 93.71% 89.10% 86.50% 84.26% 95.22% 92.58% 90.14% 97.18% 94.72% 97.49%
Survived 6.29% 10.90% 13.50% 15.74% 4.78% 7.42% 9.86% 2.82% 5.28% 2.51%
Total number of cases 4,421 4,139 3,939 3,826
3.4 feature selection
The Feature Selection phase was crucial to determine the most influential features on the
survival of colon and rectal cancer patients. In order to accomplish this the Optimize Selec-
tion operator [79] of RapidMiner was used. It implements a deterministic and optimized
selection process with decision trees and forward selection. The process was applied to each
sub-dataset for the target label. Only the features in common to all the sub-datasets, for
each cancer, were selected and used to construct the prediction models. Table 15 and Table
16 shows the selected features for colon and rectal cancer, respectively. It also shows the
meaning of the selected features.
The 6 selected features, of each cancer, were compared with a set of 18 features (shown in
Table 17) indicated by a specialist physician on colorectal cancer. These indicated attributes
were given, as common, for both types of cancer. The three sets of features were mapped to
attributes in the sub-datasets and later used to generate and evaluate the prediction models.
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Table 15.: Attributes selected in the Feature Selection process for CC.
Attribute Description
Age recode
with < 1 year old
Age groupings based on age at diagnosis (single-year
ages) of patients (< 1 year, 1-4 years, 5-9 years, ...,
85+ years)
CS Site-Specific Factor 1
The interpretation of the highest Carcinoembryonic
Antigen (CEA) test results
CS Site-Specific Factor 2 The clinical assessment of regional lymph nodes
Derived AJCC Stage Group The grouping of the TNM information combined
Primary Site
Identification of the site in which the primary tumor
originated
Regional Nodes Examined
The total number of regional lymph nodes that were
removed and examined by the pathologist
Table 16.: Attributes selected in the Feature Selection process for RC.
Attribute Description
Age recode
with < 1 year old
*
CS Extension Extension of the tumor
CS Tumor Size Size of the tumor (in mm)
Derived AJCC Stage Group *
RX Summ–Surg Prim Site
Describes a surgical procedure that removes
and/or destroys tissue of the primary site
performed as part of the initial work-up
or first course of therapy.
Sex The gender of the patient at diagnosis
* Described in Table 15.
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Table 17.: Attributes selected by a specialist physician on CC.
Attribute Description
Age at Diagnosis
The age of the patient at diagnosis
(continuous value)
CS Extension 
CS Site-Specific Factor 8 The perineural Invasion
CS Tumor Size 
Derived AJCC T, N and M The AJCC T, N and M stage (6th ed.)
Grade Grading and differentiation codes
Histologic Type
The microscopic composition of cells and/or
tissue for a specific primary
Laterality
The side of a paired organ or side of the body
on which the reportable tumor originated
Primary Site *
Race Recode
(White, Black, Other)
Race recode based on the race variables
Regional Nodes Examined *
Regional Nodes Positive
The exact number of regional lymph nodes
examined by the pathologist that were found to
contain metastases
Regional Nodes Negative
(Regional nodes examined - Regional nodes
positive)
Regional Nodes Ratio
(Regional nodes negative over Regional nodes
examined)
Relapse The relapse of the patients for colon cancer
Sex 
* Described in Table 15.
 Described in Table 16.
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3.5 data sampling
As observed, in Table 11 and Table 12, the classes are not equally represented. In order to
determine if unbalanced datasets are or not a problem, these were compared with balanced
data-sets. These balanced datasets were generated through the oversampling of the minor-
ity class, undersampling of the majority class and hybrid sampling (doing oversampling
of the minority class and undersampling of the majority class). Also was determined the
influence of the unknown values, in relation to the selected attributes. Using the Sample
(Bootstrapping) operator [82], the minority class (the “not survived” class) of each year was
oversampled to the corresponding “survived” value, for colon and rectal cancer. The major-
ity class (the “survived” class) of each year was undersampled to the corresponding “not
survived” value using the Sample operator [81], for each type of cancer. For the hybrid
sampling, the minority class was oversampled and the majority class was undersampled
for each year and cancer type, using the same operators aforementioned.
3.6 modeling
The classification strategies used in the Modeling phase consisted of ensemble methods.
The classification schemes applied were meta-classifiers. This type of classifier is used to
boost basic classifiers and improve their performance. All the possible combinations of the
classifiers were explored, according to the algorithms and type of attributes allowed. The
tested meta-classifiers were:
• Bagging [12]: Also called bootstrap aggregating. It splits the data into m different
training sets on which m classifiers are trained. The final prediction results from
the equal voting of each generated model on the correct result. Bagging is used to
improve stability and classification accuracy, reduce variance and avoid overfitting.
• AdaBoost [31]: This meta-classifier calls a new weak classifier at each iteration. A
weight distribution which indicates the weight of examples in the classification is
updated. It focuses on the examples that have been misclassified so far in order to
adjust subsequent classifiers and reduce relative error.
• Bayesian Boosting [74]: A new classification model is produced at each iteration and
the training set is reweighed so that previously discovered patterns are sampled out.
The inner classifier is sequentially applied and the resulting models are later com-
bined into a single model. The boosting operation is conducted based on probability
estimates. It is particularly useful for discovering hidden groups in the data.
• Stacking [25]: This meta-classifier is used to combine base classifiers of different types.
Each base classifier generates a model using the training set, then a meta-learner
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integrates the independently learned base classifier models into a high level classifier
by re-learning a meta-level training set. This meta-level training set is obtained by
using the predictions of base classifiers in the validation dataset as attribute values
and the true class as the target.
• Voting [46]: Each inner classifier of the meta-classifier receives the training set and
generates a classification model. The prediction of an unknown example results from
the majority voting of the derived classification models.
Since survival prediction is being handled as a classification problem, a group of basic
classifiers were selected to be used in ensembles with the above-described meta-classifiers.
The group includes some of the most widely used learners [78] available in RapidMiner.
The tested basic classifiers were:
• k-NN (Lazy Modeling) [37]: this algorithm is based on learning by analogy. The
training examples are described by n attributes and each of them represents a point
in a n-dimensional space. The test example is compared with them by searching the
pattern space and it is classified according the k training examples closest to it. The
similarity is determined in terms of a distance metric, such as the Euclidean distance.
• Naive Bayes (Bayesian Modeling) [96]: it is a simple probabilistic classifier, based on
the application of the Bayes theorem with strong (naive) assumption of independence
between every pair of features.
• Decision Tree (Tree Induction) [70]: the data is classified using a hierarchical splitting
mechanism (repeatedly splitting on the values of attributes), looking like an inverted
tree with the root at the top and it growing downwards. Each node of tree corresponds
to one of the input attributes. Normally, the recursion stops when all or the most of
the examples or instances have the same label value.
• Random Forest (Tree Induction) [48]: is generated a set of a specified number of
random trees, working like the Decision Tree. However, it uses only a random subset
of attributes for each split. The resulting model is a voting model of all the random
trees.
A total of fourteen classification schemes were explored for each type of cancer, set of
attributes (6 and 18 attributes) and type of dataset (balanced or not) for 1, 2, 3, 4, and 5
survival years. The learning combinations of meta-classifiers with basic classifiers are as
follows. The Stacking model used k-NN, Decision Tree, and Random Forest classifiers as
base learners, and a Naive Bayes classifier as a Stacking model learner. The Voting model
used k-NN, Decision Tree and Random Forest as base learners. The other models were
used in combination with each basic classifier.
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Table 18.: Table of confusion.
Labeled as Survivor Labeled as Not Survivor
Predicted as Survivor
TP
True Positives
FP
False Positives
Predicted as Not Survivor
FN
False Negatives
TN
True Negatives
3.7 evaluation
3.7.1 Cross-validation
For evaluation purposes, 10-fold cross-validation [84] was used to assess the prediction
performance of the generated prediction models and avoid overfitting. In this process, the
data is split into ten nearly identical portions, and each in turn is used for testing while
the remnant is applied for training. The process is repeated ten times, in order that in the
end every instance has been used exactly once for testing. The final validation result is the
average of the 10 repetitions.
In classification problems, there are many ways to evaluate a classifier. A confusion ma-
trix, also known as a contingency table, is usually employed to summarize the relationship
between a classifier and an instance, in a binary or binomial classification [28]. In the
context of this dissertation, a patient (the instance) can be classified as “survivor” or “not
survivor” (Table 18) after 1, 2, 3, 4 or even 5 year after the diagnosis of colon or rectal cancer.
When a patient is survivor, in a given year, and he is (well) classified as “survivor”, it is
counted as a true positive (TP). On the other hand, if he is classified as not survivor, it is
counted as a false negative (FN). If the patient is not survivor and it is (well) classified as
“not survivor”, it is counted as a true negative (TN), but if he is classified as “survivor”, it
is counted as a false positive (FP).
Each classification scheme was evaluated using metrics based on confusion matrix: the
prediction accuracy (Equation 4), the F-measure (Equation 5) and the AUC for 1, 2, 3, 4,
and 5 years. The accuracy is the percentage of correct responses among the examined cases
[11]. The F-measure is a combine of precision (a form of accuracy, also known as positive
predictive value) and recall (also known as sensitivity) measures [68]. The AUC as it is
an area, is calculated by an integral. Numerical methods, like the trapezoidal rule can be
used to approximate the integral [27]. This measure can be interpreted as the percentage
of randomly drawn data pairs of individuals that have been accurately classified in the two
populations [47], and it is commonly used as a measure of quality for classification models
[11].
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Accuracy =
(TP + TN)
(TP + TN + FP + FN)
(4)
F−measure = 2 (precision× recall)
(precision + recall)
= 2
( TP
(TP+FP) )× ( TP(TP+FN) )
( TP
(TP+FP) +
TP
(TP+FN) )
=
2TP
(2TP + FP + FN)
(5)
3.7.2 Testing
Last but not least, the 10% separated data for testing were applying for each developed
model, using the Apply Model operator [73]. A new attribute was generated to compare
the predicted value with the real value of survival, in order to determine how well the
model was able to receive new cases and give reliable predictions.
46
4
E X P E R I M E N TA L R E S U LT S
In this chapter are presented the results of performance of each developed ensemble
model. A total of 14 classification schemes were evaluated, for 6 and 18 attributes, type of
dataset (balanced or not) and from 1 to 5 years after the diagnosis and treatment of patients
with colon and rectal cancer. In order to realize the best classification scheme was calculated
the average performance of each model. From the testing phase, the percentage of wrongly
classified cases is presented for the same parameters that the models were evaluated. For
the conditional survival models, they were developed taking into account the best results
for the the survival models, thus, only a classification scheme was evaluated.
4.1 survivability prediction models
4.1.1 Colon Cancer
Figure 30 shows the average performances in terms of accuracy of the best learning
schemes for the 5 years for the models trained with unbalanced datasets, unbalanced
datasets without unknowns values, balanced oversampled datasets, balanced undersam-
pled datasets and hybrid balanced datasets, for 6 and 18 attributes. The two best values for
18 and 6 attributes are labeled.
Figure 31 shows the average performances in terms of AUC of the best learning schemes
for the 5 years for the models trained with unbalanced datasets, unbalanced datasets with-
out unknowns values, balanced oversampled datasets, balanced undersampled datasets
and hybrid balanced datasets, for 6 and 18 attributes.
Figure 32 shows the average performances in terms of F-measure of the best learning
schemes for the 5 years for the models trained with unbalanced datasets, unbalanced
datasets without unknowns values, balanced oversampled datasets, balanced undersam-
pled datasets and hybrid balanced datasets, for 6 and 18 attributes.
Figure 33 shows the average percentage of wrongly classified cases of the best learn-
ing schemes for the 5 years for the models trained with unbalanced datasets, unbalanced
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Figure 30.: Average survivability percentage accuracy for colon cancer: comparison of the
18-attribute models with the 6-attribute models for the best learning schemes.
datasets without unknowns values, balanced oversampled datasets, balanced undersam-
pled datasets and hybrid balanced datasets, for 6 and 18 attributes.
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Figure 31.: Average survivability AUC for colon cancer: comparison of the 18-attribute mod-
els with the 6-attribute models for the best learning schemes.
4.1.2 Rectal Cancer
Figure 34 shows the average performances in terms of accuracy of the best learning
schemes for the 5 years for the models trained with unbalanced datasets, unbalanced
datasets without unknowns values, balanced oversampled datasets, balanced undersam-
pled datasets and hybrid balanced datasets, for 6 and 18 attributes.
Figure 35 shows the average performances in terms of AUC of the best learning schemes
for the 5 years for the models trained with unbalanced datasets, unbalanced datasets with-
out unknowns values, balanced oversampled datasets, balanced undersampled datasets
and hybrid balanced datasets, for 6 and 18 attributes.
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Figure 32.: Average F-measure performance for colon cancer: comparison of the 18-attribute
models with the 6-attribute models for the best learning schemes.
Figure 36 shows the average performances in terms of F-measure of the best learning
schemes for the 5 years for the models trained with unbalanced datasets, unbalanced
datasets without unknowns values, balanced oversampled datasets, balanced undersam-
pled datasets and hybrid balanced datasets, for 6 and 18 attributes.
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Figure 33.: Average percentage of wrongly classified cases for colon cancer: comparison
of the 18-attribute models with the 6-attribute models for the best learning
schemes.
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Figure 34.: Average survivability percentage accuracy for rectal cancer: comparison of the
18-attribute models with the 6-attribute models for the best learning schemes.
Figure 37 shows the average percentage of wrongly classified cases of the best learn-
ing schemes for the 5 years for the models trained with unbalanced datasets, unbalanced
datasets without unknowns values, balanced oversampled datasets, balanced undersam-
pled datasets and hybrid balanced datasets, for 6 and 18 attributes.
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Figure 35.: Average survivability AUC for rectal cancer: comparison of the 18-attribute mod-
els with the 6-attribute models for the best learning schemes.
4.2 conditional survival prediction models
4.2.1 Colon Cancer
Table 19 shows the performance values for the conditional survival prediction models of
colon cancer.
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Figure 36.: Average F-measure performance for rectal cancer: comparison of the 18-attribute
models with the 6-attribute models for the best learning schemes.
4.2.2 Rectal Cancer
Table 20 shows the performance values for the conditional survival prediction models of
rectal cancer.
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Figure 37.: Average percentage of wrongly classified cases for rectal cancer: comparison
of the 18-attribute models with the 6-attribute models for the best learning
schemes.
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Table 19.: Performance values for the conditional survival prediction models of colon can-
cer.
Target Labels
survived the 1st year survived the 2nd year survived the 3rd year survived the 4th year
2 Year 3 Year 4 Year 5 Year 3 Year 4 Year 5 Year 4 Year 5 Year 5 Year
Accuracy 97.39% 97.27% 97.44% 97.02% 98.32% 97.62% 97.09% 98.48% 97.55% 98.59%
AUC 0.981 0.985 0.986 0.984 0.979 0.983 0.979 0.974 0.969 0.945
F-measure 88.74% 92.72% 98.35% 98.03% 89.77% 98.64% 98.29% 99.20% 98.68% 99.27%
Wrongly Classified Cases (%) 2.57% 3.08% 2.45% 3.08% 1.80% 2.58% 3.61% 1.62% 2.60% 1.10%
Total number of testing cases 1752 1552 1424 1362
Table 20.: Performance values for the conditional survival prediction models of rectal can-
cer.
Target Labels
survived the 1st year survived the 2nd year survived the 3rd year survived the 4th year
2 Year 3 Year 4 Year 5 Year 3 Year 4 Year 5 Year 4 Year 5 Year 5 Year
Accuracy 96.31% 95.41% 94.59% 94.03% 98.24% 96.16% 94.76% 97.21% 96.27% 97.99%
AUC 0.952 0.957 0.952 0.947 0.947 0.941 0.939 0.884 0.912 0.874
F-measure 70.13% 78.99% 96.87% 96.45% 79.15% 97.91% 97.09% 98.56% 98.02% 98.97%
Wrongly Classified Cases (%) 3.67% 3.05% 6.31% 6.31% 2.61% 4.35% 5.22% 2.05% 2.51% 2.12%
Total number of testing cases 491 460 438 425
4.3 discussion
The total of the 18 attributes were indicated by the expert physician as being shared
for the survivability prediction for both cancers. The Feature Selection process picked 6
distinct attributes, for each type of cancer. The selected attributes, with the exception of
the site-specific factors (the interpretation of the highest CEA test results and the clinical
assessment of regional lymph nodes) for colon cancer and the surgical procedure for rectal
cancer, they were all connected with the features indicated by the specialist physician. Still
within the Feature Selection process, all the selected attributes had the same weight. It
can be a limitation of the used software. Although when using ensemble learning to train
models, each basic classifier in a meta-classifier is assigned a weight.
From a general observation of the results, for both types of cancer, the ensemble models
using decision trees (excepting the Bayesian Boosting modeling) and k-NN demonstrated a
very high performance values. Stand out all values of wrongly classified cases are the same,
inside of each cancer type and dataset type, for models which only used k-NN classifier in
the learning process.
For colon cancer, the model which presented the general highest values of performance
(values from cross-validation) was the Stacking model trained with balanced oversampled
dataset, with the average values of 98.23% and 97.04% for accuracy, 0.992 and 0.990 of AUC
and 98.22% and 97.00% of F-measure, for 18 and 6 attributes, respectively. However, when
the testing data was applied to this model and the prediction values were compared to the
real values the percentage of wrongly classified cases was 19.38% and 56.78%, for 18 and
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6 attributes, respectively. These values compared with the values of the models trained
with unbalanced datasets are very high. The best model, in terms of wrongly classified
cases percentage, was the Stacking model trained with the unbalanced dataset and without
unknown cases (3.03% for 6 attributes). The values for 18 attributes of this type of dataset
were not able to be calculated due the insufficient number of registries after remove the
unknown values. Comparing the performance values of the Stacking model of the balanced
oversampled dataset and the Stacking model of the unbalanced without unknown cases
dataset, they are very close. For the 6 attributes, the model of the oversampled dataset was
slightly better in 0.34% of accuracy, 0.003 of AUC and 1.84% of F-measure.
Still for the colon cancer, comparing the values of performance between models with
18 and 6 attributes, the 18 attributes models showed a slightly better performance values.
However, it should be noted that, in addition to the close performances, the difference
between the number of attributes used is important. To apply the attributes in a practical
way (for instance, into a tool), the health care professional will lose much time if he must
introduce 18 attributes. This is a critical point, may lead to non-use of the tool. The results
show that it is possible to build a model with less than half of the features indicated by the
expert physician, with similar performances.
For rectal cancer, the observed results were very identical. However, slightly lower.
The model which presented the general highest values of performance (values from cross-
validation) also was the Stacking model trained with balanced oversampled dataset, with
the average values of 98.52% and 96.61% for accuracy, 0.992 and 0.982 of AUC and 98.52%
and 96.53% of F-measure, for 18 and 6 attributes, respectively. The values of wrongly clas-
sified cases percentage were 42.25% and 32.22%. The best model, in terms of wrongly clas-
sified cases percentage, was the Stacking model trained with the unbalanced dataset and
without unknown cases (4.79% for 6 attributes). The difference of performance values of
the Stacking model trained with the balanced oversampled dataset and the Stacking model
trained with the unbalanced dataset and without unknown cases, were slightly higher rel-
ative to the same obtained values for colon cancer. The Stacking model trained with the
balanced oversampled dataset was better in 2.16% of accuracy, 0.017 of AUC and 8.45% of
F-measure.
As mentioned throughout the dissertation, the intention was to develop the conditional
survival models using the same conditions which the best found model for the prediction
survival after treatment models. Taking into account the performance values (from cross-
validation), the percentage of wrongly classified cases and their relations with the number
of attributes, the Stacking model trained with the unbalanced dataset and without unknown
cases was selected to develop the conditional survival models for colon and rectal cancer,
using the 6 selected attributes by Feature Selection process. These models presented high
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values of performance and a low percentage of wrongly classified cases, similar to values
obtained for the prediction survival after treatment models, for each type of cancer.
Comparing this approach with others mentioned in Chapter 2, for colon cancer, fewer
features were necessary to develop the prediction model. Moreover, in the approach fol-
lowed in [3], the closest to the one followed herein for the prediction after treatment, the
best model of colon cancer survival prediction was based on a Voting classification scheme,
with prediction accuracies of 90.38%, 88.01%, and 85.13% and AUCs of 0.96, 0.95, and 0.92
for years 1, 2 and 5. In this work, the model considered better presented less attributes and
a larger time window. The performance values for each year also were always better. With
95.85%, 96.74%, 96.88%, 97.01% and 97.03% of accuracy and 0.982, 0.985, 0.988, 0.988 and
0.988 of AUC for years 1 to 5.
To calculate the conditional survival for colon cancer patients, the best model in Chapter
2, presented by Chang et al. [18] had a C-index of 0.816 (a model from 0 to 5 years).
The average of AUC for the correspondent models in this work was 0.977, presenting one
characteristic more.
Relative to rectal cancer, the best model in Chapter 2 for prevision after treatment had a C-
index of 0.70 (from 1 to 10 years) by Valentini et al. [98]. In this work, the model considered
better presented three less attributes and the AUC values were 0.957, 0.968, 0.968, 0.968 and
0.963, for 1 to 5 years, respectively. Producing a average of 0.965, also a higher value than
the existing solution.
The last but not the least, to calculate the conditional survival of rectal cancer patients, the
actual solution presents a value of 0.75 of C-index (from 0 to 5 years). The corresponding
developed model, in this work, produced a average of 0.931 of AUC.
As such, the present work represents an improvement and was able to achieve consider-
ably better results.
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D E V E L O P M E N T O F A N A P P L I C AT I O N
Over the last years, the industry of wireless devices, such as handheld PCs and even
smartphones, gone through tremendous advancements. Accordingly, these devices have
become increasingly popular and common [88]. Throughout the last decade, mobile phones
have gone from being simple phones to being handheld pocket-sized computers. Their
powerful capabilities, since the processing and on-board computing capacity till the high
quality of screens, incite the development of applications [8].
Statistics shows that in 2016 the number of smartphone users is forecast to reach 2,08
billion. It is projected that just over 36% of the world population will use a smartphone
by 2018, up from about 10% in 2011 [67]. According to data from the International Data
Corporation (IDC) Worldwide Quarterly Mobile Phone Tracker, the Android of Google and
iOS of Apple are the two most popular smartphone operating systems [22].
For the health care industry, mobile applications yielded new boundaries in providing
better care and services to patients. Moreover, it is making a revolution in the way of the
information is managed in this industry and redefine the doctor – patient communication
[88, 64]. Mobile devices and their applications have provided many benefits for health care
professionals. The portability of mobile applications can increase the productivity of these
professionals. It grants a rapid access to information and multimedia resources, allowing
them to make decisions more quickly with a lower error rate, increasing the quality of
patient documentation and improved workflow patterns [100, 59].
This chapter describes how the models were made available to health care professionals.
5.1 requirements gathering
The current section is intended to specify the functional and non functional requirements
to construct an application able to help the health care professionals in their functions,
specifically to help physicians to predict the survivability for colorectal patients. The speci-
fication of the requirements are represented in a textual mode. To the requirements gather-
ing were used insight techniques and was analyzed of the dissertation proposal. However,
it will not specify the technique used in each requirement.
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5.1.1 Functional Requirements
The functional requirements describe the functionality that is expected the system to have.
The application must:
• Allow the selection of the type of prediction;
• Allow the selection of the cancer type for which the user want to obtain a prediction;
• Allow the insertion of values for a set of selected characteristics to the prediction
models;
• Allow the choice of the value to insert, for a characteristic, from a set of listed values;
• Allow the obtain of the survival prediction, according to the inserted data, for 1, 2, 3,
4 and 5 years after the diagnosis and treatment;
• Allow the obtain of the conditional survival prediction, according to the inserted
data, for 2, 3, 4 or 5 years after the diagnosis and treatment, according to the years
that patient already survived;
• Allow the obtain of a confidence value for each year of prediction;
• Allow the visualization of the prediction data through a bar chart;
• Allow the insertion of the selected characteristics of the patients into a new registry
of a database;
• Not allow user submit the form of characteristics if some them have not any value
selected;
• Not allow user submit the selected characteristics if the mobile device is not connected
to the internet.
5.1.2 Non-functional requirements
To ensure a quality mobile tool, were defined some essential points that describe how the
system works. These point are commonly known as non-functional requirements and are
related with the use of the application in terms of performance, usability, reliability, secu-
rity, availability, maintenance and technologies involved. The non-functional requirements
recognized are:
• Available of a mobile application;
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• Available of the mobile application using open source technologies, constantly update
and evolution;
• The mobile application should have responsive design and to adapt to different mo-
bile devices;
• The mobile application should have an appealing appearance;
• The visualization of the characteristics and predictions should be of a easy compre-
hension;
• The insertion of the values for the characteristics should be easy;
• The solution should cover the principal mobile platforms (iOS, Android and Windows
Phone).
5.2 architecture
To made available the developed models was projected a hybrid mobile application, ap-
propriate to smartphones and tablets. On the back-end of this tool, were developed two
web services: one for give the survivability prediction response of colon or rectal cancer
to user (applying the models) and another to recalculate the models. Figure 38 shows the
architecture of the application. It will be discussed in more detail in the next subsections.
Figure 38.: Architecture of the developed tool.
5.2.1 Survival Prediction Application
Hybrid approach fits between web and native methodology. To construct a native appli-
cation is necessary know the correspondent programing language, which vary according
to the operating system target. In the case of iOS it is Objective-C or Swift, for Android it
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is Java and for Windows Phone it is C#. In a web-based approach, the mobile device will
not have any application specific components installed. The applications are browser based
and are platform independent. However, the accessability could be conditioned because it
is exposed to cross space communication vulnerabilities [71]. For that reason, it cannot be
appropriate to frequent uses. A hybrid application is developed applying web technologies
(mainly, HTML5, CSS and JavaScript) and gets executed inside native container on the mo-
bile device. It is suitable to multiple platforms and is distributable through an application
store, like native applications. This type of approach can have an inferior performance, com-
paring with native applications [71]. However, mobile devices in nowadays have powerful
capabilities and the lapse of performance are not really noted.
The application was created with intention to be a cross platform tool, suitable to smart-
phones and tablets, either with the android, Windows Phone or even with the iOS operating
system.
The application was developed using AngularJS, Ionic Framework, and Cordova. An-
gularJS is a popular framework of JavaScript, mainly maintained by Google [5]. Ionic is
an HTML5 SDK open source, which offers a library of mobile-optimized HTML, CSS and
JavaScript CSS components, gestures, and tools for building interactive apps [40]. It also
was optimized for AngularJS. Cordova wraps the HTML/JavaScript app into a native con-
tainer which can access the device functions of several platforms [21]. These functions are
exposed via a unified JavaScript API, for an easily accessing to the full native functionality.
5.2.2 Survival Prediction Model Server Application
In order to apply the developed models, was developed a web service with representa-
tional state transfer (REST) architecture. The RESTful architecture style is based on web-
standards and the HTTP protocol. It was chosen due to the declarative nature and other
characteristics of it, such as being light-weight, easily accessible and scalable [107].
The web service was developed in Java with the Java API for RESTful Web Services (JAX-
RS) [45] reference implementation Jersey [41], an open source framework used for Java
projects and distributed mainly via Maven [55].
The data is sent over the HTML POST method when the health care professional submits
the values of characteristics for a particular patient through the application. The REST-
ful web service, integrating the RapidMiner software through its API, receives the values
and applies them to the corresponding model, which is in a XML file. The response of
the patient survivability for 1 to 5 years is returned in a JSON format and a bar chart is
constructed.
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5.2.3 Online Learning Server Application
The submitted data from each patient and its outcomes are added to a database for
posteriorly, after several insertions, recalculate all the models, keeping them up-to-date.
Thereunto, was developed another RESTful web service, with a similar structure to that
developed for patient survivability respond. It provides an independent service because of
the time necessary for recompute the models.
The data is inserted into a NoSQL database (MongoDB [56]) and for each 10% new reg-
istries (in relation of the initial cases) the models for 1 to 5 years are recalculated, generating
5 XML files which replace the used files in 5.2.2. In this way, it will be possible for users
to dynamically feed new cases to the prediction system and make it change in order to
provide better survival predictions. This type of model could also prove to be very useful
when integrated in computer-interpretable guideline systems, such as the one described in
[61], as a way to provide dynamic knowledge to rule-based decision support.
5.3 interface
Figure 39a shows the first screen which appears when the application is initiated. Here,
user has the opportunity to choose the type of prediction he wants do: calculate the surviv-
ability after treatment or calculate the conditional survival. Clicking on the menu (Figure
39b) are visible all the options available in this application.
Choosing calculate the survivability after treatment (Figure 40a) or calculate the condi-
tional survival (Figure 40b), a new menu comes. Here, user has the occasion to select the
cancer type for the prediction.
5.4 use case
5.4.1 Survivability After Treatment Calculators
A typical use case is getting a prediction for colon cancer survivability. Supposing a
physician is treating a patient diagnosed with colon cancer, once the type of cancer in the
home screen is set (as shown in Figure 39b), the health care professional inserts the values
for the selected features (Figure 41a). All features, except for the age of the patient, are filled
in by choosing the value from a list of available options. By submitting a case of a patient
with 55 years old, having a positive/elevated carcinoembryonic antigen value, with clinical
assessment of regional lymph nodes of not clinically evident, with the primary site of the
cancer being in the sigmoid colon, with stage 0 and with 5 as the number of regional nodes
examined, the values are sent to the Survival Prediction Model Server Application and the
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(a) Home screen. (b) Menu.
Figure 39.: Home screen and menu of the application.
outcome is calculated. The prediction is always provided in the form of confidence values
for a positive prediction, i.e., the confidence that the patient will survive. This is displayed
in a new screen in the form of a bar chart (Figure 41b). For the stage of the patient, the
physician can choose between the TNM system or the grouped stage, known as AJCC stage.
The results show that, while the model was able to predict with 100% confidence that the
patient will survive the first three years, the confidence of his surviving the fourth and fifth
years is 0%.
To predict the survivability of a patient diagnosed with rectal cancer, the procedure is
similar to the one used for colon cancer. Figure 42a shows what happen when the user
not filled out all the characteristics and Figure 42b shows what happen when the internet
connection fails, i.e., the submit button of the application is not enabled.
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(a) Survivability after treatment calculator. (b) Conditional survival calculator.
Figure 40.: Calculator menus.
5.4.2 Conditional Survival Calculators
To predict the survivability of a patient who already survived some time after the diag-
nosis and treatment for colon or rectal cancer, the procedure is similar to the one used in
survival after treatment calculators. The only difference is the selection of the year that
patient already survived. Supposing a physician wants to know the survival of the patient
diagnosed with colon cancer, after he/she survived the first year after treatment. The health
care professional inserts the values for the features (Figure 43a). The results (Figure 43b)
show that, the model was able to predict, one year after treatment of colon cancer, with
100% confidence that the patient will survive more two years. The confidence for the fourth
and fifth years after treatment, remained at 0%.
To predict the conditional survival of a patient diagnosed with rectal cancer, the proce-
dure is similar to the one used for the conditional survival of colon cancer patients.
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(a) Characteristics of Colon Cancer. (b) Results for Colon Cancer.
Figure 41.: Colon Cancer Survivability After Treatment Calculator (accessed by a smart-
phone).
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(a) Characteristics are not filled. (b) Internet connection fail.
Figure 42.: Error control of application.
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(a) Characteristics of Colon Cancer (Conditional
Survival).
(b) Results for Colon Cancer (Conditional Sur-
vival)).
Figure 43.: Colon Cancer Conditional Survival Calculator (accessed by a tablet).
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C O N C L U S I O N S , P U B L I C AT I O N S A N D F U T U R E W O R K
6.1 conclusions
This work involved the use of different meta-classification schemes to construct survival
prediction models, for colon and rectal cancer patients after treatment and after some time
after treatment. The best models found was a Stacking classification scheme, combining
k-NN, Decision Tree, and Random Forest classifiers as base learners and a Naive Bayes
classifier as a stacking model learner. These models were trained with an unbalanced
dataset, without unknown cases for the selected features. Therefore, the objectives 1, 2 and
3 were fulfilled with success.
The ideal number of features for colon and rectal cancer survival prediction was found to
be 6. The selected set for colon cancer includes: age, CS site-specific factor 1, CS site-specific
factor 2, derived AJCC stage group, primary site, and regional nodes examined. For rectal
cancer, the selected set was: age, CS extension, CS tumor size, derived AJCC stage group,
RX summ–surg prim site and the sex of patient at time of diagnosis. The selected attributes
for colon and rectal cancer were not all the same, only the age and the stage were common.
It was observed that the most of the selected features were connected with the features
indicated by the specialist physician. It was also observed that the selected features are less
than half of the features given by specialist physicians (18 attributes), and presented similar
performance values. In this manner, the objectives 4, 5 and 6 were fulfilled with success.
Many studies [19, 50] show how important the problem of using imbalanced datasets is,
from both the algorithmic and performance perspectives. During this work, three sampling
forms were tested and the results were compared with unbalanced datasets. Was concluded
that the sampling improved the performance values. However, the models trained with
balanced dataset were those that classified worst. Concluding, in this manner, that not
always the best models (with better performance values) are those that classify better.
The developed models were able to present a better performance than the existing ap-
proaches and overall with fewer features. It was determined that not all models are avail-
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able to health professionals and those that are, only two has the minimum characteristics
to be considered mobile friendly. Consequently, the objective 7 was fulfilled with success.
The best developed models were available to health care professionals into a cross-platform
mobile application, in order to assist them in carrying out their duties at any time. To en-
sure that the model is able to adapt and adjust, an online learning server was created. In
this way, it will be possible for users to dynamically feed new cases to the prediction system
and make it change in order to provide better survival predictions. Therefore, the objectives
8 and 9 were fulfilled with success.
6.2 publications
The current work originated two conference papers with the references:
• Ana Silva, Tiago Oliveira, Paulo Novais, Jose´ Neves and Pedro Lea˜o. Developing an
Individualized Survival Prediction Model for Colon Cancer. 7th International Confer-
ence on Ambient Intelligence, 2016.
• Ana Silva, Tiago Oliveira, Vicente Julian, Jose´ Neves and Paulo Novais. A Mobile
and Evolving Tool to Predict Colorectal Cancer Survivability. 12th IFIP International
Conference on Artificial Intelligence Applications and Innovations, 2016.
And a journal article with the reference:
• Ana Silva, Tiago Oliveira, Paulo Novais, Jose´ Neves and Pedro Lea˜o. Treating Colon
Cancer Survivability Prediction as a Classification Problem. Advances in Distributed
Computing and Artificial Intelligence Journal, 5(1).
6.3 prospect for future work
Future work includes the continuous improving of the models and of the tool. The in-
crease of the time windows, for the conditional survival calculators, is one of the proposals.
In order to better understand comprehend the capacities of the developed tool, it will be
interesting carrying out prospective tests.
Additionally, the adaptation of the models to Portuguese reality would be an important
goal, because there is no Portuguese tool for this purpose. Compare a Portuguese tool with
the current work would be enriching and would give possibility for physicians to prove,
or not, that the lifestyle among people with different cultures influence the prediction for
these types of cancer.
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A
S C R I P T T O P R O C E S S T H E S E E R D ATA S E T
In this appendix is presented the script used to convert the raw data from SEER database
into a csv file.
a.1 c# code
using System;
using System.Collections.Generic;
using System.IO;
using System.Linq;
using System.Text;
using System.Threading.Tasks;
namespace seerdata2csv
{
class Program
{
static void Main(string[] args)
{
SEER2CSV();
}
public static void SEER2CSV()
{
try
{
string[] lines = File.ReadAllLines(@"//seer/COLRECT.TXT");
StreamWriter sw = new StreamWriter("seer_data.csv", true);
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sw.WriteLine("Patient ID number;
Registry ID;
Marital Status at DX;
Race/Ethnicity;
Spanish/Hispanic Origin;
NHIA Derived Hispanic Origin;
Sex;
Age at diagnosis;
Year of Birth;
Sequence Number|Central;
Month of diagnosis;
Year of diagnosis;
Primary Site;
Laterality;
Histology (92-00) ICD-O-2;Behavior (92-00) ICD-O-2;
Histologic Type ICD-O-3;
Behavior Code ICD-O-3;
Grade;Diagnostic Confirmation;
Type of Reporting Source;
EOD|Tumor Size;
EOD|Extension;
EOD|Extension Prost Path;
EOD|Lymph Node Involv;
Regional Nodes Positive;
Regional Nodes Examined;
EOD|Old 13;
Digit EOD|Old 2;
Digit EOD|Old 4 Digit;
Coding System for EOD;
Tumor Marker 1;
Tumor Marker 2;
Tumor Marker 3;
CS Tumor Size;
CS Extension;
CS Lymph Nodes;
CS Mets at Dx;
CS Site-Specific Factor 1;
CS Site-Specific Factor 2;
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CS Site-Specific Factor 3;
CS Site-Specific Factor 4;
CS Site-Specific Factor 5;
CS Site-Specific Factor 6;
CS Site-Specific Factor 25;
Derived AJCC T;
Derived AJCC N;
Derived AJCC M;
Derived AJCC Stage Group;
Derived SS1977;
Derived SS2000;
Derived AJCC|Flag;
Derived SS1977|Flag;
Derived SS2000|Flag;
CS Version Input Original;
CS Version Derived;
CS Version Input Current;
RX Summ|Surg Prim Site;
RX Summ|Scope Reg LN Sur;
RX Summ|Surg Oth Reg/Dis;
RX Summ|Reg LN Examined;
Reason for no surgery;
RX Summ|Radiation;
RX Summ|Rad to CNS;
RX Summ|Surg / Rad Seq;
RX Summ|Surgery Type;
RX Summ|Scope Reg 98-02;
RX Summ|Surg Oth 98-02;
SEER Record Number;
Over-ride age/site/morph;
Over-ride seqno/dxconf;
Over-ride site/lat/seqno;
Over-ride surg/dxconf;
Over-ride site/type;
Over-ride histology;
Over-ride report source;
Over-ride ill-define site;
Over-ride Leuk, Lymph;
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Over-ride site/behavior;
Over-ride site/eod/dx dt;
Over-ride site/lat/eod;
Over-ride site/lat/morph;
SEER Type of Follow-up;
Age Recode <1 Year olds;
Site Recode ICD-O-3/WHO 2008;
Recode ICD-O-2 to 9;
Recode ICD-O-2 to 10;
ICCC site recode ICD-O-3/WHO 2008;
ICCC site rec extended ICD-O-3/WHO 2008;
Behavior Recode for Analysis;
Histology Recode|Broad Groupings;
Histology Recode|Brain Groupings;
CS Schema v0204+;
Race recode (White, Black, Other);
Race recode (W, B, AI, API);
Origin recode NHIA (Hispanic, Non-Hisp);
SEER historic stage A;
AJCC stage 3rd edition (1988-2003);
SEER modified AJCC Stage 3rd ed (1988- 2003);
SEER Summary Stage 1977 (1995-2000);
SEER Summary Stage 2000 (2001-2003);
Number of primaries;
First malignant primary indicator;
State-county recode;
Cause of Death to SEER site recode;
COD to site rec KM;Vital Status recode;
IHS Link;
Summary stage 2000 (1998+);
AYA site recode/WHO 2008;
Lymphoma subtype recode/WHO 2008;
SEER Cause-Specific Death Classification;
SEER Other Cause of Death Classification;
CS Tumor Size/Ext Eval;
CS Lymph Nodes Eval;
CS Mets Eval;
Primary by international rules;
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ER Status Recode Breast Cancer (1990+);
PR Status Recode Breast Cancer (1990+);
CS Schema -AJCC 6th ed (previously called v1);
CS Site-Specific Factor 8;
CS Site-Specific Factor 10;
CS Site-Specific Factor 11;
CS Site-Specific Factor 13;
CS Site-Specific Factor 15;
CS Site-Specific Factor 16;
Lymph vascular invasion;
Survival months;
Survival months flag;
Survival months { presumed alive;
Survival months flag { presumed alive;
Insurance recode (2007+);
Derived AJCC-7 T;
Derived AJCC-7 N;
Derived AJCC-7 M;
Derived AJCC-7 Stage Grp;
Breast Adjusted AJCC 6th T (1988+);
Breast Adjusted AJCC 6th N (1988+);
Breast Adjusted AJCC 6th M (1988+);
Breast Adjusted AJCC 6th Stage (1988+);
CS Site-Specific Factor 7;
CS Site-Specific Factor 9;
CS Site-Specific Factor 12;
Derived HER2 Recode (2010+);
Breast Subtype (2010+);
Lymphomas: Ann Arbor Staging (1983+)");
foreach (string line in lines)
{
sw.WriteLine(line.Substring(0, 8).Trim() + ’;’ +
line.Substring(17, 10).Trim() + ’;’ +
line.Substring(18, 1).Trim() + ’;’ +
line.Substring(19, 2).Trim() + ’;’ +
line.Substring(21, 1).Trim() + ’;’ +
line.Substring(22, 1).Trim() + ’;’ +
line.Substring(23, 1).Trim() + ’;’ +
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line.Substring(24, 3).Trim() + ’;’ +
line.Substring(27, 4).Trim() + ’;’ +
line.Substring(34, 2).Trim() + ’;’ +
line.Substring(36, 2).Trim() + ’;’ +
line.Substring(38, 4).Trim() + ’;’ +
line.Substring(42, 4).Trim() + ’;’ +
line.Substring(46, 1).Trim() + ’;’ +
line.Substring(47, 4).Trim() + ’;’ +
line.Substring(51, 1).Trim() + ’;’ +
line.Substring(52, 4).Trim() + ’;’ +
line.Substring(56, 1).Trim() + ’;’ +
line.Substring(57, 1).Trim() + ’;’ +
line.Substring(58, 1).Trim() + ’;’ +
line.Substring(59, 1).Trim() + ’;’ +
line.Substring(60, 3).Trim() + ’;’ +
line.Substring(63, 2).Trim() + ’;’ +
line.Substring(65, 2).Trim() + ’;’ +
line.Substring(67, 1).Trim() + ’;’ +
line.Substring(68, 2).Trim() + ’;’ +
line.Substring(70, 2).Trim() + ’;’ +
line.Substring(72, 13).Trim() + ’;’ +
line.Substring(85, 2).Trim() + ’;’ +
line.Substring(87, 4).Trim() + ’;’ +
line.Substring(91, 1).Trim() + ’;’ +
line.Substring(92, 1).Trim() + ’;’ +
line.Substring(93, 1).Trim() + ’;’ +
line.Substring(94, 1).Trim() + ’;’ +
line.Substring(95, 3).Trim() + ’;’ +
line.Substring(98, 3).Trim() + ’;’ +
line.Substring(101, 3).Trim() + ’;’ +
line.Substring(104, 2).Trim() + ’;’ +
line.Substring(106, 3).Trim() + ’;’ +
line.Substring(109, 3).Trim()+ ’;’ +
line.Substring(112, 3).Trim() + ’;’ +
line.Substring(115, 3).Trim() + ’;’ +
line.Substring(118, 3).Trim() + ’;’ +
line.Substring(121, 3).Trim() + ’;’ +
line.Substring(124, 3).Trim() + ’;’ +
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line.Substring(127, 2).Trim() + ’;’ +
line.Substring(129, 2).Trim() + ’;’ +
line.Substring(131, 2).Trim() + ’;’ +
line.Substring(133, 2).Trim() + ’;’ +
line.Substring(135, 1).Trim() + ’;’ +
line.Substring(136, 1).Trim() + ’;’ +
line.Substring(137, 1).Trim() + ’;’ +
line.Substring(138, 1).Trim() + ’;’ +
line.Substring(139, 1).Trim() + ’;’ +
line.Substring(140, 6).Trim() + ’;’ +
line.Substring(146, 6).Trim() + ’;’ +
line.Substring(152, 6).Trim() + ’;’ +
line.Substring(158, 2).Trim() + ’;’ +
line.Substring(160, 1).Trim() + ’;’ +
line.Substring(161, 1).Trim() + ’;’ +
line.Substring(162, 2).Trim() + ’;’ +
line.Substring(165, 1).Trim() + ’;’ +
line.Substring(166, 1).Trim() + ’;’ +
line.Substring(167, 1).Trim() + ’;’ +
line.Substring(168, 1).Trim() + ’;’ +
line.Substring(169, 2).Trim() + ’;’ +
line.Substring(173, 1).Trim() + ’;’ +
line.Substring(174, 1).Trim() + ’;’ +
line.Substring(175, 2).Trim() + ’;’ +
line.Substring(177, 1).Trim() + ’;’ +
line.Substring(178, 1).Trim() + ’;’ +
line.Substring(179, 1).Trim() + ’;’ +
line.Substring(180, 1).Trim() + ’;’ +
line.Substring(181, 1).Trim() + ’;’ +
line.Substring(182, 1).Trim() + ’;’ +
line.Substring(183, 1).Trim() + ’;’ +
line.Substring(184, 1).Trim() + ’;’ +
line.Substring(185, 1).Trim() + ’;’ +
line.Substring(186, 1).Trim() + ’;’ +
line.Substring(187, 1).Trim() + ’;’ +
line.Substring(188, 1).Trim() + ’;’ +
line.Substring(189, 1).Trim() + ’;’ +
line.Substring(190, 1).Trim() + ’;’ +
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line.Substring(191, 2).Trim() + ’;’ +
line.Substring(198, 5).Trim() + ’;’ +
line.Substring(203, 4).Trim() + ’;’ +
line.Substring(207, 4).Trim() + ’;’ +
line.Substring(217, 3).Trim() + ’;’ +
line.Substring(220, 3).Trim() + ’;’ +
line.Substring(223, 1).Trim() + ’;’ +
line.Substring(225, 2).Trim() + ’;’ +
line.Substring(227, 2).Trim() + ’;’ +
line.Substring(229, 3).Trim() + ’;’ +
line.Substring(232, 1).Trim() + ’;’ +
line.Substring(233, 1).Trim() + ’;’ +
line.Substring(234, 1).Trim() + ’;’ +
line.Substring(235, 1).Trim() + ’;’ +
line.Substring(236, 2).Trim() + ’;’ +
line.Substring(238, 2).Trim() + ’;’ +
line.Substring(240, 1).Trim() + ’;’ +
line.Substring(241, 1).Trim() + ’;’ +
line.Substring(242, 2).Trim() + ’;’ +
line.Substring(244, 1).Trim() + ’;’ +
line.Substring(245, 5).Trim() + ’;’ +
line.Substring(254, 5).Trim() + ’;’ +
line.Substring(259, 5).Trim() + ’;’ +
line.Substring(264, 1).Trim() + ’;’ +
line.Substring(265, 1).Trim() + ’;’ +
line.Substring(266, 1).Trim() + ’;’ +
line.Substring(267, 2).Trim() + ’;’ +
line.Substring(269, 2).Trim() + ’;’ +
line.Substring(271, 1).Trim() + ’;’ +
line.Substring(272, 1).Trim() + ’;’ +
line.Substring(273, 1).Trim() + ’;’ +
line.Substring(274, 1).Trim() + ’;’ +
line.Substring(275, 1).Trim() + ’;’ +
line.Substring(276, 1).Trim() + ’;’ +
line.Substring(277, 1).Trim() + ’;’ +
line.Substring(278, 1).Trim() + ’;’ +
line.Substring(279, 2).Trim() + ’;’ +
line.Substring(281, 3).Trim() + ’;’ +
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line.Substring(284, 3).Trim() + ’;’ +
line.Substring(287, 3).Trim() + ’;’ +
line.Substring(290, 3).Trim() + ’;’ +
line.Substring(293, 3).Trim() + ’;’ +
line.Substring(296, 3).Trim() + ’;’ +
line.Substring(299, 1).Trim() + ’;’ +
line.Substring(300, 4).Trim() + ’;’ +
line.Substring(304, 1).Trim() + ’;’ +
line.Substring(305, 4).Trim() + ’;’ +
line.Substring(309, 1).Trim() + ’;’ +
line.Substring(310, 1).Trim() + ’;’ +
line.Substring(311, 3).Trim() + ’;’ +
line.Substring(314, 3).Trim() + ’;’ +
line.Substring(317, 3).Trim() + ’;’ +
line.Substring(320, 3).Trim() + ’;’ +
line.Substring(323, 2).Trim() + ’;’ +
line.Substring(325, 2).Trim() + ’;’ +
line.Substring(327, 2).Trim() + ’;’ +
line.Substring(329, 2).Trim() + ’;’ +
line.Substring(331, 3).Trim() + ’;’ +
line.Substring(334, 3).Trim() + ’;’ +
line.Substring(337, 3).Trim() + ’;’ +
line.Substring(340, 1).Trim() + ’;’ +
line.Substring(341, 1).Trim() + ’;’ +
line.Substring(347, 1).Trim());
}
sw.Flush();
sw.Close();
}
catch (Exception ex)
{
Console.WriteLine(ex.ToString());
Console.ReadLine();
}
}
}
}
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R A P I D M I N E R P R O C E S S E S
In this appendix is presented the workflows constructed in the RapidMiner software to
develop the prediction models.
b.1 preprocessing process
Figure B.1.44.: Preprocessing phase, part 1 of 2.
Figure B.1.45.: Preprocessing phase, part 2 of 2.
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b.2 split dataset
Figure B.2.46.: Split dataset phase.
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B.3. Feature Selection
b.3 feature selection
Figure B.3.47.: Feature selection phase.
b.4 sampling data
Figure B.4.48.: An example of the sampling data phase.
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b.5 modeling and evaluation
Figure B.5.49.: An example of the modeling and evaluation phase.
94
CD E TA I L S O F R E S U LT S
In this appendix is presented all the details of the results. It was divided by cancer type
and dataset type used to train the models.
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Appendix C. details of results
c.1 survivability prediction models
c.1.1 Colon Cancer
Unbalanced Models Without Unknowns
Table C.1.1.: Survivability percentage accuracy of unbalanced models without unknowns,
for colon cancer.
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C.1. Survivability Prediction Models
Table C.1.2.: Survivability percentage AUC of unbalanced models without unknowns, for
colon cancer.
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Table C.1.3.: F-measure performance of unbalanced models without unknowns, for colon
cancer.
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C.1. Survivability Prediction Models
Table C.1.4.: Percentage of wrongly classified cases of unbalanced models without un-
knowns, for colon cancer.
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Unbalanced Models
Table C.1.5.: Survivability percentage accuracy of unbalanced models, for colon cancer.
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C.1. Survivability Prediction Models
Table C.1.6.: Survivability percentage AUC of unbalanced models, for colon cancer.
Table C.1.7.: F-measure performance of unbalanced models, for colon cancer.
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Table C.1.8.: Percentage of wrongly classified cases of unbalanced models, for colon cancer.
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C.1. Survivability Prediction Models
Hybrid Models
Table C.1.9.: Survivability percentage accuracy of hybrid models, for colon cancer.
Table C.1.10.: Survivability percentage AUC of hybrid models, for colon cancer.
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Table C.1.11.: F-measure performance of hybrid models, for colon cancer.
Table C.1.12.: Percentage of wrongly classified cases of hybrid models, for colon cancer.
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C.1. Survivability Prediction Models
Oversampled Models
Table C.1.13.: Survivability percentage accuracy of oversampled models, for colon cancer.
Table C.1.14.: Survivability percentage AUC of oversampled models, for colon cancer.
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Table C.1.15.: F-measure performance of oversampled models, for colon cancer.
Table C.1.16.: Percentage of wrongly classified cases of oversampled models, for colon can-
cer.
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C.1. Survivability Prediction Models
Undersampled Models
Table C.1.17.: Survivability percentage accuracy of undersampled models, for colon cancer.
Table C.1.18.: Survivability percentage AUC of undersampled models, for colon cancer.
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Table C.1.19.: F-measure performance of undersampled models, for colon cancer.
Table C.1.20.: Percentage of wrongly classified cases of undersampled models, for colon
cancer.
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C.1. Survivability Prediction Models
c.1.2 Rectal Cancer
Unbalanced Models Without Unknowns
Table C.1.21.: Survivability percentage accuracy of unbalanced models without unknowns,
for rectal cancer.
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Table C.1.22.: Survivability percentage AUC of unbalanced models without unknowns, for
rectal cancer.
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C.1. Survivability Prediction Models
Table C.1.23.: F-measure performance of unbalanced models without unknowns, for rectal
cancer.
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Table C.1.24.: Percentage of wrongly classified cases of unbalanced models without un-
knowns, for rectal cancer.
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C.1. Survivability Prediction Models
Unbalanced Models
Table C.1.25.: Survivability percentage accuracy of unbalanced models, for rectal cancer.
Table C.1.26.: Survivability percentage AUC of unbalanced models, for rectal cancer.
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Table C.1.27.: F-measure performance of unbalanced models, for rectal cancer.
Table C.1.28.: Percentage of wrongly classified cases of unbalanced models, for rectal cancer.
114
C.1. Survivability Prediction Models
Hybrid Models
Table C.1.29.: Survivability percentage accuracy of hybrid models, for rectal cancer.
Table C.1.30.: Survivability percentage AUC of hybrid models, for rectal cancer.
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Table C.1.31.: F-measure performance of hybrid models, for rectal cancer.
Table C.1.32.: Percentage of wrongly classified cases of hybrid models, for rectal cancer.
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C.1. Survivability Prediction Models
Oversampled Models
Table C.1.33.: Survivability percentage accuracy of oversampled models, for rectal cancer.
Table C.1.34.: Survivability percentage AUC of oversampled models, for rectal cancer.
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Table C.1.35.: F-measure performance of oversampled models, for rectal cancer.
Table C.1.36.: Percentage of wrongly classified cases of oversampled models, for rectal can-
cer.
118
C.1. Survivability Prediction Models
Undersampled Models
Table C.1.37.: Survivability percentage accuracy of undersampled models, for rectal cancer.
Table C.1.38.: Survivability percentage AUC of undersampled models, for rectal cancer.
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Table C.1.39.: F-measure performance of undersampled models, for rectal cancer.
Table C.1.40.: Percentage of wrongly classified cases of undersampled models, for rectal
cancer.
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